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Abrégé/ Résumé 
Les lésions surrénaliennes  surviennent  dans la population générale à une fréquence 
d’environ  2-3%. Parmi les anomalies génétiques identifiées jusqu’à présent dans les 
tumeurs surrénaliennes, les mutations somatiques de β-caténine  sont  les plus prévalentes. 
Elles sont présentes dans environ 20% des  adénomes et carcinomes cortico-surrénaliens.  
β-caténine est l’élément central de la voie canonique de WNT qui joue un rôle crucial dans 
le développement embryonnaire, l’homéostase et la tumourigenèse. Les mutations 
activatrices de β-caténine conduisent à l’accumulation nucléaire de β- caténine qui interagit 
avec les TCF/LEF-1 qui active la transcription des gènes cibles. Les gènes cibles de  β-
caténine, varient et dépendent du contexte cellulaire. Dans la glande surrénale, les gènes  
cibles de β-caténine  sont inconnus. Nous avons effectué des études de microarray qui nous 
ont permis d’identifier 490 transcrits dérégulés dans les adénomes corticosurrénaliens 
porteurs de mutations ponctuelles de β-caténine. L’expression aberrante d’ISM1, RALBP1, 
PDE2A, CDH12, ENC1, PHYHIP et CITED2 dans les adénomes porteurs de mutations de 
β-caténine a été confirmée par PCR en temps réel. Le traitement des cellules humaines de 
carcinome cortico-surrénalien H295R (mutation de CTNNB1, Ser45Prol) avec les 
inhibiteurs de β-caténine/TCF (PKF115-584 et PNU74654) ont confirmé l'implication de β-
caténine dans la régulation  transcriptionelle d’ISM1, RALBP1, PDE2A, ENC1 et CITED2. 
En conclusion, nos travaux ont conduit à l’identification de nouveaux gènes  cibles de β-
catenin impliqués dans la tumourigenèse cortico-surrénalienne.   
Mots clés : Glandes surrénales, Cortex surrénalien, Adénome cortico-surrénalien, 
Voie de signalisation de WNT,  Microarray, Tumourigenèse, CTNNB1/β-caténine, 
PKF115-584, H295R 
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Abstract 
Adrenal lesions occur in the general population at a prevalence of about 2-3%. Several 
mutations have been identified in adrenocortical tumours. β-catenin mutations were 
recently found to be the most frequent genetic alteration in both sporadic adrenocortical 
adenomas and carcinomas (20-30%). β-catenin is the central player in canonical Wnt 
signaling which plays a key role in organ/ gland development, maintenance of homeostasis 
and tumourigenesis. Activation of Wnt signaling by altered regulation of β-catenin levels 
evokes β-catenin accumulation in the nucleus, and interaction with the TCF/LEF-1 proteins 
that activates the transcription of target genes.  These target genes are believed to be highly 
cell and context specific and are linked to developmental and cell cycling functions. β-
catenin target genes in adrenocortical tumours are unknown. Using microarray technology, 
we found 490 transcripts that are deregulated in adrenocortical adenomas harbouring β-
catenin activating mutations in comparison to non mutated adenomas and normal adrenal 
glands. These genes differ highly in function and many are poorly characterized genes. 
Differential expression of ISM1, RALBP1, PDE2A, CDH12, ENC1, PHYHIP and CITED2 
in adenomas with activating β-catenin mutations was confirmed by real-time PCR. 
Treatment of human adrenocortical carcinoma cells, H295R (CTNNB1 Ser45Prol), with β-
catenin/TCF inhibitors (PKF115-584 and PNU74654) further confirmed the implication of 
β-catenin on the transcriptional regulation of ISM1, RALBP1, PDE2A, ENC1 and CITED2. 
In conclusion, we have found new potential β-catenin target genes that may be involved in 
adrenocortical tumourigenesis.    
Key words: Adrenal gland, adrenocortical adenoma, adrenocortical carcinoma, WNT 
signaling, microarray, tumourgenesis, CTNNB1/β-catenin, PKF115-584, H295R 
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Chapter 1. Review of literature 
Section 1.  The Adrenal Gland 
1.1. Adrenal gland physiology 
  The adrenal gland is a small gland (4 grams in adults) situated at the upper 
extremity of both kidneys in mammals (Figure 1A, page 2).  It is composed of two 
completely distinctive zones, the medulla and the cortex (Figure 1B, page 2) surrounded by 
a capsule. The medulla is the central part and represents 10-20% of the adrenal gland 
weight in humans. The medulla is composed primarily of chromaffin cells and secretes 
epinephrine and norepinephrin. The cortex is yellow in healthy individuals and is itself 
composed of three zones (zona glomerulosa, zona fasciculata, zona reticucularis) each 
responsible for the synthesis of different hormones. The cells in each layer have slightly 
different structures, reflecting their different functions (Figure 1D, page2). Note that the 
focus of this project was on aspects involving only the adrenal cortex. 
The zona glomerulosa is responsible for aldosterone production and is incapable of 
producing the other hormones secreted by the cortex (see section 1.2). The zona fasciculata 
is the largest of three zones and makes up to 75% of the total cortex. The cells within this 
zone are much larger and contain high lipid content. The zona reticularis is a compact layer 
surrounding the medulla and produces androgens and cortisol along with the zona 
fasciculata.   
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Figure 1 : Adrenal gland and its zones.  (A) Picture showing location of the adrenal gland 
above the kidney. www.nlm.nih.gov (B) Lateral cut of an adrenal gland showing location of the 
medulla and the cortex www.thyroidinstitute.org/images/adrenal_gland. (C,D) Hematoxylin and 
eosin staining of the adrenal cortex tissue (C) showing that it is separated into three zones;  
reticularis; fasciculata (zF); and, glomerulosa (D) http://www.ouhsc.edu/histology 
1.2. Adrenocortical Steroidogenesis 
Steroids are a type of organic compound that contain a core structure of 4 rings 
(cyclohexanes and one cyclopentane) that are joined to each other. Steroid structures are 
highly conserved in both the animal and plant kingdoms. Steroid specificity is derived from 
diverse modifications of the core structure catalyzed by different enzymes.  In mammals the 
core structure is provided by cholesterol.  
1.2.1. Synthesis of Adrenal Steroids 
In the adrenal gland, cholesterol can be synthesized de novo but the majority of the 
cholesterol comes from plasma lipoproteins which are absorbed by the cells through 
membrane receptors (1). Once inside the cell, cholesterol is modified by cytochromes P450 
enzymes. Steroid synthesis reactions are limited by the steroidogenic acute regulatory 
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protein (StAR) which controls cholesterol translocation to the mitochondrial outer 
membrane. 
Adrenal steroidogenesis for the production of cortisol, aldosterone and sex 
hormones is depicted in Figure 2 (page 4). The CYP11A1 (cytochrome P450, family 11, 
subfamily A, polypeptide 1 or P450SC) enzyme which is expressed in all adrenal cells 
transforms the cholesterol to pregnenolone. Pregnenolone is then converted to progesterone 
or 17α-Hydroxypregnenolone by 3βHSD (3-β-hydroxysteroid dehydrogenase/Δ-5-4 
isomerase) or CYP17 (17α-hydroxylase) respectively. Progesterone can also be converted 
to 17α-hydroxypregnenolone. In the adrenal zona fasciculata and reticularis cortisol and 
corticosterone are synthesized respectively from 17α-hydroxypregnenolone and 
progesterone by the enzymes CYP21 (21-hydroxylase) and CYP11B1 (steroid 11β-
hydroxylase). The zona glomerulosa lacks the enzymes required for the production of sex 
hormones, and cortisol. Instead the zona glomerulosa is responsible for the conversion of 
corticosterone by CYP11B2 (aldosterone synthase) to aldosterone. CYP11B2 is only 
expressed in the adrenal zona glomerulosa which makes this zone specific for the 
production of aldosterone (2).   
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Figure 2:  Steroidogenesis pathway in the adrenal gland and gonads. (2)  
Although most sex hormones are produced by the gonads, the adrenal gland also 
produces the androgens DHEA, DHEA-S and androstenedione. DHEA is produced by both 
zona fasciculata and reticularis but only cells of the reticularis express SULT2A1 to 
produce DHEA-S; the active form of DHEA.  
1.2.2. Control of steroid production 
 Being of pivotal importance to homeostasis, adrenal steroid secretion is under tight 
control by regulatory pathways. Control of the two main hormones, cortisol and 
aldosterone will therefore be briefly discussed.   
Cortisol, a glucocorticoid hormone is released in response to stress. Its primary 
functions are to increase blood sugar and glycogen storage in the liver (3), aid in fat, protein 
and carbohydrate metabolism (4), and to suppress the immune system (5). It is controlled 
by hypothalamic secretion of corticotropin-releasing hormone (CRH), which in turn 
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triggers pituitary secretion of Adrenal Corticotrophic Hormone (ACTH); ACTH is carried 
by the blood to the adrenal cortex where it triggers glucocorticoid secretion. The amount of 
cortisol produced and secreted in the blood undergoes diurnal variation, with peak 
production in the early morning and nadir during sleeping hours.  Excess cortisol produced 
by the adrenal gland inhibits further production of CRH and ACTH leading to an inhibitory 
loop regulation (Figure 3).    
 
 
Figure 3: Human cortisol production in the adrenal gland. Neural signals trigger CRF 
secretion by the hypothalamus. In turn, this signals to the pituitary to release ACTH which 
stimulates the adrenal gland to release cortisol. Cortisol acts on the hypothalamus and the pituitary 
to have a negative feedback effect on the release of CRH and ACTH respectively. Figure from 
http://models.cellml.org   
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Aldosterone is a mineralocorticoid hormone synthesized exclusively in the adrenal 
zona glomerulosa. Aldosterone regulates homeostasis by increasing the reabsorption of 
sodium and water and the secretion of potassium in the kidneys. This increases blood 
volume leading in part to increased blood pressure. Aldosterone secretion is controlled by 
the  renin-angiotensin-aldosterone system (6). In the liver, renin activity (the rate limiting 
factor of the secretion of aldosterone) leads to the production of angiotensin I. Angiotensin 
is cleaved by the angiotensin-converting-enzyme to angiotensin II. Angiotensin II increases 
aldosterone secretion from the zona glomerulosa by increasing transcription of CYP11B2 
(6). Angiotensin II itself also acts to inhibit renin production creating a negative feedback 
loop of regulation. ACTH also stimulates aldosterone production indirectly by stimulating 
the formation of deoxycorticosterone (7), a precursor of aldosterone (Figure 2, page 4). 
1.3. Adrenal gland development  
Adrenocortical cell development in human embryos is due to two independent 
events. 1) The adrenal cortex arises from adrenogonadal progenitors that first appear in the 
fourth week of gestation as a thickening of the coelomic epithelium between the urogenital 
ridge and the dorsal mesentery (8). Cells destined to generate the adrenal cortex migrate to 
the cranial pole of the mesonephros, which creates the foetal adrenal gland by the eighth 
week of gestation. This fetal adrenal gland contains an inner cluster of large cells, termed 
the foetal zone (Figure 4, page 7). 2) By week eight (Figure 4, page 7), a second group of 
cells form a compact  outer zone of cells, termed the definitive zone (9). Cells in the 
definitive zone, unlike the foetal zone, lack expression of CYP17 (9).  
At week nine (Figure 4, page 7), the foetal and definitive zone (foetal adrenal 
cortex) become encapsulated. The capsule is thought to provide growth factors that are 
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important in  mediating  adrenal  growth and differentiation, such as insulin like growth 
factors 1 and 2 (IGF1 and 2) (9). Also at nine weeks, neural crest-derived cells migrate into 
the foetal adrenal cortex and differentiate, hence forming the catecholamine-producing 
chromaffin cells (10), which remain scattered until birth. This differentiation of the neural 
crest cells is triggered by the glucocorticoids secreted by the cortex (10). 
 At birth the adrenal gland is relatively larger than the adult gland due to the size of 
the fetal cortex (Figure 4, page 7). Preceding birth, further significant changes of the 
adrenal gland occurs. First the medulla is formed by compaction of the chromaffin cells 
(Figure 4, page 7). After three weeks there is full regression of the fetal zone followed by 
encapsulation of the medulla. Finally, the definitive zone of the human adrenal cortex 
differentiates into the three zones of the adrenal gland (the outer zona glomerulosa, the 
middle zona fasciculata, and the inner zona reticularis) (9) (Figure 4, page 7). It must also 
be noted that at this time events controlling adrenal cortex zonation are not fully 
understood. 
 
Figure 4: Developmental events of the adrenal gland from embryo to adult. Modified 
from Hammer, G. D. et al.2005 (11) 
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Section 2.  Tumours of the adrenal cortex 
 
Adrenocortical adenomas are benign tumours of the adrenal cortex which are 
extremely common (present in 1-10% of persons at autopsy). They have been detected as 
incidental findings with increasing frequency in recent years, due to increased use of CT 
scans and magnetic resonance imaging in a variety of medical settings. As seen in table I, 
adenomas are the most common of adrenocortical tumours. About 30-50% of adrenal 
tumors are discovered from endocrine problems (such as in Cushing’s syndrome). Other 
lesions are found by chance with no clinical manifestations and are referred to as 
incidentalomas. Most of the incidentalomas are benign but about 4% of them are malignant 
(see table I).  
Table I: Classification of adrenal incidentalomas. From a study of patients from le Study 
Group of the Italian Society of Endocrinology on Adrenal Incidentalomas (12) 
Non secreting  adrenocortical adenomas 74% 
Secreting  adrenocortical  adenomas   
 Cortisol-secreting  9,60% 
 Aldosterone-secreting  1,40% 
Pheochromocytomas   4.2% 
Adrenocortical carcinomas  4% 
Metastases    0,70% 
Other lesions     16,40% 
 
2.1. Adrenocortical adenomas 
  An adenoma is a benign tumour of glandular origin. Adenomas can grow from 
many organs including the colon, the adrenal glands, the pituitary gland, the thyroid, etc. 
Although benign, over time they may progress to become malignant  in specific tissue such 
as in the colon, however this malignant transformation has never been described in the 
adrenal gland. Adrenocortical adenomas have the potential to cause serious health 
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complications by producing large amounts of hormones in an unregulated, non-feedback-
dependent manner. Typically adenomas are well limited, encapsulated nodular lesions of 
the adrenal cortex ranging from a couple of millimeters to a few centimeters. Histological 
examination shows that cells in adenomas are similar to those of the normal cortex with 
high lipid content. Most adenomas are non-functional, meaning that they do not produce 
any glucocorticoids (cortisol), mineralocorticoids (aldosterone), and/or sex steroids 
(testoterone, estrogens). In about 15% of cases, adrenocortical adenomas are "functional",  
and secrete abnormally high levels of  the glucocorticoid cortisol or the mineralcorticoid 
aldosterone which results respectively in endocrine disorders such as Cushing's syndrome 
and  Conn's syndrome (hyperaldosteronism).  
2.1.2. Cortisol-secreting adrenocortical adenomas 
  Overproduction of cortisol is the most common characteristic of functional 
adrenocortical adenomas. Elevated cortisol levels are the cause of Cushing’s syndrome 
which leads to high blood pressure, diabetes, osteoporosis, skin atrophy, infection and, 
many other symptoms. In most cases Cushing’s syndrome is due to elevated ACTH levels 
caused by improper functioning of the pituitary gland (pituitary tumour). Elevated ACTH 
levels can lead to overproduction of cortisol and an enlargement of the adrenal gland (13). 
In other cases, adrenocortical adenomas can produce hypercortisolism independently of 
ACTH (ACTH-independent Cushing’s syndrome) (14, 15).  
2.1.3. Aldosterone-secreting adenomas 
Adenomas, which secrete abnormally high levels of aldosterone cause primary 
aldosteronism. Hyperaldosteronism can be asymptomatic or associated with hypertension 
and hypokaliemia (16).  
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2.2. Adrenal Hyperplasias  
 Adrenal hyperplasias are much less common than adenomas. There are 2 main 
subtypes of primary bilateral ACTH-independant hyperplasias; 1) ACTH-independent 
macronodular adrenal hyperplasia (AIMAH) and 2) micronodular adrenal hyperplasia 
which includes primary pigmented nodular adrenocortical disease (PPNAD). Bilateral 
adrenal hyperplasias cause approximately 10 to 15% of adrenal Cushing’s syndrome (17, 
18)  
2.2.1. ACTH-independent micronodular adrenal hyperplasias and PPNAD  
PPNAD is diagnosed mainly in young adults (19) and is characterized by normal 
sized adrenal glands containing several small cortical pigmented nodules (20). PPNAD may 
be isolated or associated with a multiple neoplasia syndrome, Carney complex (CNC), 
which can include spotty skin pigmentation, heart and skin myxomas and various endocrine 
tumours. PPNAD is the most frequent endocrine manifestation of Carney complex (19). 
Germline mutations of the PRKAR1A gene encoding for the types 1-α regulatory subunit of 
cAMP dependent protein kinase A are found in more than 50% of cases of CNC and are 
also frequent in isolated PPNAD (21-23). More recently, using a genome-wide scan 
approach, Horvath et al., identified germline mutations in the gene encoding 
phosphodiesterase 11A4 (PDE11A) in patients with CS secondary to micronodular 
adrenocortical hyperplasia (24).  
2.2.2. ACTH-independent macronodular adrenal hyperplasia 
AIMAH may rarely develop during the first year of life associated with McCune-
Albright syndrome (25), but the majority of cases are detected during the fifth or sixth 
decade of life (26). The most frequent presentation of AIMAH is with clinical or 
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subclinical CS (18). Usually, computed tomography reveals clear enlargement of both 
adrenal glands. Histological examination is characterized by non-pigmented nodules 
composed of two types of cells, those with clear cytoplasm (lipid-rich) that form cordon 
nest-like structures, and those with a compact cytoplasm (lipid-poor) that form small nest or 
island-like structures (27).    
 AIMAH was most often reported as sporadic cases, but there have been increasing 
reports of familial AIMAH  suggesting an autosomal dominant pattern of transmission (28). 
AIMAH may be rarely associated with syndromes where genetic defects have been 
identified such as MEN 1 (menin), familial adenomatous polyposis (APC) and hereditary 
leiomyomatosis and renal cell cancer disorder (fumarate hydratase) (27, 29).  In addition, 
AIMAH is found in a subgroup of patients with Mc Cune-Albright syndrome, where 
activating mutations of the Gsα subunit occur in the adrenal gland during embryogenesis 
and lead to constitutive activation of the cAMP signaling and CS.  Fragoso et al, identified 
gsp mutations in 3 of 5 patients with AIMAH and CS without any manifestations of Mc 
Cune-Albright syndrome (30). In a patient with AIMAH an ACTH receptor (MC2R) 
mutation was identified which lead to impaired desensitization and internalization of the 
receptor associated to apparent constitutive activity (31). Recently, two mutations in the 
same allele of MC2R was identified in a patient with clinical hypersensitivity to ACTH 
(32). 
Although, there is some evidence of cylic AMP-dependent signaling aberrations, no 
mutations were found in PRKAR1A gene in AIMAH (33). However, somatic losses of the 
17q22-24 region which contains  PRKAR1A gene was found frequently in AIMAH samples 
(33).   
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2.2.3. Congenital hyperplasia (CAH) 
 Congenital hyperplasia (CAH) represents another type of adrenal hyperplasia and is 
one of the most frequent adrenal disorders observed in children at birth. CAH is 
characterized by deficiency in 21-hydroxylase expression or other adrenal specific 
steroidogenic enzymes in less frequent cases. Deficiency in cortisol production leads to 
excess of ACTH secretion which stimulates adrenal hyperplasia growth (34).  
 
2.3. Adrenocortical carcinoma (ACC) 
Adrenocortical carcinoma (ACC) is a rare, highly aggressive cancer of adrenal 
cortical cells, which may occur both in children and adults. ACC may be "functional", 
producing steroid hormones and consequent endocrine dysfunction similar to that seen in 
many adrenocortical adenomas, or non-functional. Due to their location deep in the 
retroperitoneum, most ACCs are not diagnosed until they have grown quite large. They 
frequently invade large vessels, such as the renal vein. ACC metastasizes via the 
lymphatics and through the blood, to the lungs and other organs. The overall prognosis of 
the disease is poor and present treatments are limited leading to poor survival. ACCs like 
adenomas are often sporadic of origin and can also be associated with familial syndromes 
like Li-Fraumeni (35) and Beckwith-Weidemann (36) syndrome. In the recent years, 
progress to determine key genes and pathways involved in the pathogenesis of ACCs has 
been slow, in part due to the rarity of these tumours. 
2.4. Genetic and pathway alterations of adrenocortical tumours 
Genetic alterations either hereditary or sporadic are the key to cancer development. 
Alterations that affect either tumour supressors or cause overexpression of oncogenes can 
13 
 
cause alterations of signaling pathway, resulting in uncontrolled cell growth and tumour 
formation. A number of hereditary syndromes with known genetic alterations are associated 
with adrenocortical tumours (Table II). Interestingly, a number of these genetic alterations 
may also be found in sporadic adrenocortical tumours like in the MEN, TP53 and 
PRKAR1A genes. The following section will discuss several pathways/genes thought to 
play a role in adrenal tumour development and progression, summarized in table II. 
Table II: Genes /and associate familiale  syndromes in adrenocortical tumours. 
Gene/Protein Type Chromosomal 
location 
Syndromes Types of 
adrenal  
tumours 
Familial/ sporadic References 
TP53/p53 Tumour supressor 17p13.1 Li-Fraumeni ACC Both (37) 
IGF2/IGFII 
Growth factor 11p15.5 
Beckwith-Weideman 
syndrome 
ACC Sporadic (38, 39) 
MEN1/ Menin 
Tumour supressor 11q13 
Multiple endocrine 
neoplasia type 1 
ACC/AA/AIMAH Both (40, 41) 
CTNNB1/B-catenin Transcription factor 3p21 None ACC/AA/PPNAD Sporadic  
ras/RAS ( HRAS, 
KRAS,NRAS) 
small GTP binding 
proteins 
11p15.5, 12p12.1, 
1p13.2 
None 
ACC/AA (N and 
K-ras only) 
Sporadic (42, 43) 
PRKAR1A/ PRKAR1A 
protein kinase 
PKA regulator, 
Tumour supressor 
17q22-24 
Carney Complex PPNAD/AA Both (44, 45) 
PDE11A / 
Phosphodiesterase 
11A PDE8B/ 
Phosphodiesterase 
8B 
Phosphodiesterase 
2q31-35 None 
Micronodular 
adrenal 
hyperplasias 
Familial (24, 46) 
GNAS1/GNAS 
G protein signaling 20q13.2 
McCUne-Albright 
syndrome 
AIMAH Both (30) 
 
2.4.1. Alterations of TP53 
  The TP53 tumour supressor gene codes for the protein p53. The p53 protein 
controls cell proliferation by controlling the G1/S cell cycle check point and can initiate 
program cell death in presence of DNA damage. TP53 mutations are highly common in 
human cancers (47). A hereditary germline mutations of TP53 located at 17p13.1 are the 
underlying genetic abnormality in 70% of Li-Fraumeni cancer syndrome cases (37). The 
Li-Fraumeni syndrome is a syndrome linked to an increased risk of breast cancer, soft 
tissue sarcoma, brain cancer, leukemia as well as ACC (48). ACC associated with Li-
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Fraumeni syndrome occurs at an early age (children and young adults). In pediatric ACC, 
about 50-80% of sporadic cases are also associated with germline TP53 mutations (49, 50). 
In adults, 1/3 of sporadic ACCs have somatic TP53 mutations while in adenomas somatic 
mutations are uncommon suggesting that these alterations happen late in tumourogenesis 
(51-54). Furthermore ACC with somatic but not germline TP53 mutations are associated 
with poor prognosis and are considered to represent a more malignant phenotype.  
2.4.2. Insulin Growth Factor 2 (IGF2) 
The IGF pathway involves two ligands (IGF1 and IGF2), two receptors (IGFR1 and 
2) as well as 6 IGF binding proteins (1 to 6)(55). IGF-2 is expressed during the embryonic 
and foetal stages of adrenal development and contributes to growth and differentiation, 
whereas expression is kept low in the adult adrenal (56-58). IGF-I and IGF-II, can both act 
as adrenocortical mitogens by promoting progression through the G1/S phase of the cell 
cycle via activation of phosphatidylinositol 3-kinase (PI3K) and the AKT protein kinase 
(59, 60).  
  Transcriptional analysis by microarray technology has shown IGF2 as the most 
over-expressed gene in human ACC compared with adrenocortical adenomas or normal 
tissues (61-63). IGF1 has not been observed to be overexpressed in ACC (38). In human 
ACC alterations at chromosome 11p15 by genetic or epigenetic, are present in about 90% 
of cases (64, 65) and this is believed to be the cause of overexpressed IGF2.  
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Figure 5 : Alterations of 11p15 locus and IGF-II overexpression in ACC. The imprinted 
11p15 locus contains the CDKN1C (p57kip2), IGF-II, and H19 genes. In normal differentiated 
tissue (on the left), only the paternal allele of the IGF-II gene is expressed, whereas only the 
maternal alleles of CDKN1C and H19 are expressed. Paternal isodisomy is usually observed in 
adrenal cancers (on the right) with loss of the maternal allele at 11p15. This leads to the 
overexpression of IGF-II and decreased expression of CDKN1C and H19. Modified from Libe et al 
. 2007(65) 
The IGF2 locus (11p15) (Figure 5) is parentally imprinted, and normally only the paternal 
allele is expressed (66). Two other imprinted genes in this region, H19 and p57KIP2, are 
expressed only from the maternal allele. The H19 mRNA is not translated and serves to 
inhibit IGF2expression. The p57KIP2 gene encodes a cyclin-dependent kinase inhibitor 
involved in the G1/ S phase of the cell cycle. Mutation and/or aberrant expression of 
imprinted genes in the IGF2 locus causes Beckwith-Wiedemann syndrome (BWS), a 
syndrome associated with adrenal hyperplasia and ACC (67).  
Due to the significance and frequency of IGF-II upregulation in sporadic ACC, this 
growth factor and its receptors are considered candidates for molecularly targeted drug 
therapy. Overexpression of the IGF-1 receptor (IGF1R) has also been observed in ACC 
(39, 68). IGF1R antagonists cause growth inhibition in vitro and of human ACC xenografts 
in nude mice (60). Early clinical trials with humanized IGF1R antibodies have also shown 
to be promising in PHASE1 trials for ACC treatment (69) 
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2.4.3. PRKAR1A and other cAMP pathway alterations 
The regulatory R1A subunit of protein kinase A (PRKAR1A) is the main regulator 
of protein kinase A (PKA) activity and a key component of the cAMP signaling pathway 
that has been the subject of many studies in endocrine tumourigenesis (70, 71). The 
PRKAR1A gene is located at the 17q22–24 locus and is, as previously mentioned implicated 
in the Carney complex (CNC; (21, 23) and PPNAD (44, 45)). Heterozygous inactivating 
germline mutations of PRKAR1A have been demonstrated in about 45 to 65% from two 
studies in CNC families (23), (72). Somatic PRKAR1A mutations have also been found in 
sporadic secreting adrenocortical adenomas, with similar characteristics to those of PPNAD 
(73). Mutations of PRKAR1A are not found in ACC although LOH at 17q is found in 
adenomas.  In adenomas, LOH is restricted  to the PRKAR1A locus (17q22–24) but in ACC 
LOH effect a larger area of 17q (65). This suggests that PRKAR1A alterations may play a 
role at the early onset of tumoural growth but that this effect is minimized in malignant 
growth. 
 More recently inactivation germline mutations in two phosphodiesterases (PDE) 
genes PDE11A and PDE8B have been found (24, 46) in adrenal micronodular adrenal 
hyperplasias. PDE11A is a dual specificity PDE which catalyzes hydrolysis of cAMP and 
cGMP (74). Of the four known isoforms of PDE11A (A1 to A4) only A4 is reported to be 
expressed in the adrenal gland (74). PDE11A is located at 2q31-35 and fluorescent in situ 
hybridization (FISH) studies of tumours have demonstrated 2q allelic loss in patients with 
PDE11A inactivating mutations. Strangely, inactivation mutations of PDE11A are also 
found in the general population although at a lower frequency. This suggests low 
penetrence of PDE11A mutations and that other PDE’s must be present in the adrenal gland 
to compensate for the lack of PDE11A activity. 
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 The PDE8B gene codes for the PDE with the highest cAMP affinity (75). It is 
highly expressed in the adrenal gland and is harboured in the 5q13 locus, a region thought 
to be associated with micronodular adrenocortical disease (MAD)(46). In HEK293 cells, 
cAMP levels are significantly increased following transfection with mutant PDE8B (76).  
Another type of cAMP pathway alteration involves activating somatic mutations in 
the gene coding for GNAS (Gsα). GNAS is a member of the G protein family, which form a 
heterotrimers with β, γ subunits that participate in signal transduction. GNAS has intrinsic  
GTpase activity and stimulates cAMP production (77). Mutants found of GNAS, prevent 
downregulation of cAMP signaling (27). GNAS  mutations are associated with AIMAH and 
the McCune-Albright syndrome (MAS) which is primarily associated with fibrous 
dysplasias (78).  
Up to date, alterations in multiple players of cAMP pathway leading to increased 
cAMP signaling appear to be the main cause of nodular adrenocortical disease. Clearly the 
adrenal gland seems highly susceptible to changes in the cAMP pathway with adrenal 
hyperplasias being the most predominant clinical manifestation in humans with germline 
mutations in PDE11A, PDE8B and PRKAR1A. In contrast, cAMP pathway alterations are 
not found in ACC and thus are not believed to lead to malignant growth, but may be 
associated with early tumor formation. 
2.4.4. Ras pathway alterations 
Ras proteins are membrane associated small GTPases proteins and are referred to 
molecular switches in signaling pathways that control proliferation, differentiation, death 
and mobility. The three ras proteins (H, N, and K) are the most commonly mutated 
oncogenes in human cancers (79). Controversial data is present in the literature;  Lin et al, 
(42) found K-ras mutations in about 50% of tumoural tissues of Conn’s adenomas and 
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Yashiro et. al, who found N-ras mutations in 7 of 56 (12.5%) of all tumours tested (3 of 24 
(12.5%) carcinomas and 4 of 32 (12.5%) adenomas (Yashiro et al 1994), while Moul et al.  
(80) and Ocker et al.(81)  did not identify any Ras mutations.  In a more recent study K-ras 
and N-ras mutations were each found in one out of 35 ACCs (43). In this study, 2 (5.7%) 
and 4 ACCs (11.4%) were also found to carry BRAF and EGFR TK domain mutations 
respectively (43). K-ras mutation found by  Lin et al. were active in ACC (Lin, Hsu et al. 
2000)  and lead to increases in steroidogenic enzyme expression and an increase in cortisol 
production when transfected into normal adrenal cells (82). These data suggest that EGFR-
Ras-Raf-MEK-ERK pathway alterations are present in only a subset of ACC.   
2.4.5. MEN 1 
 Adrenal tumours are also associated with mutations in the MEN 1 gene which 
codes for the Menin protein. A heterozygous inactivating germline mutation of MEN 1 can 
be found in about 90% of families affected by multiple endocrine neoplasia type 1 (MEN 
1). Menin Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary 
cancer syndrome presented mostly by tumors of the parathyroids, endocrine pancreas and 
anterior pituitary. About 25–40% of MEN 1 patients are affected by adrenocortical tumours 
and/or hyperplasias (41, 83). In most cases, these tumours are non-functional adenomas and 
are rarely seen in ACC.  Somatic mutations in the MEN 1 gene are known but are very rare 
in all adrenocortical tumours (40, 83). The 11q13 locus containing the MEN1 gene 
frequently losses heterozygosity at a greater frequency in ACC’s (90%) compared to 
adenomas ( 20%), however expression of the MEN1 gene does not differ between them 
(83),  suggesting that the MEN1 gene does not play a role in the progression of sporadic 
adrenal tumours.   
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2.5. Adrenocortical tumourigenesis 
2.5.1. Clonality of adrenocortical tumours 
Determining tumour clonality is important to establish the origin as well as the 
mechanisms dictating tumour progression. Mono-clonality indicates that tumour 
progression is the end result of a or multiple genetic mutations, whereas polyclonality  
suggests that tumour cells are affected by local or systemic stimuli (59). Three X-
chromosome inactivation studies have up to date been performed to determine the clonality 
of adrenocortical tumours.  All three studies  are in agreement and show that ACC consists 
of monoclonal populations of cells,  adenomas  tumours  are both  monoclonal as well as 
polyclonal (64, 84, 85). Hyperplasias on the other hand are only polyclonal (84). Variation 
observed in adenomas tumours may be explained by different mechanisms or are due to 
observation of a multiple steps, within a common mechanism. These observations have 
been suggestive of a multistep (clonal) genetic model of adrenocortical tumour 
development. 
2.5.2. Models of adrenocortical tumour development 
Unlike other cancers, the factors and steps leading to adrenocortical tumour 
development is still under debate. In colon cancer progression of adenoma to carcinoma 
was proposed, however this sequence is not recognized in adrenocortical tumourogenesis.   
Adrenocortical tumours comparative genomic hybridization (CGH) studies have 
shown a positive correlation between adrenocortical tumour size and the number of 
chromosomal alterations, supporting the hypothesis that chromosomal changes accumulate 
during tumour progression (65, 86). In benign lesions  the average number of chromosomal 
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aberrations per tumour cell is low (87), with chromosomal gains occurring often of  9q 
(14%-22%) (87) (88) and 17q (26-35%) (88). Chromosomal  losses also occur, although 
less often, with the most common being at chromosomal 1p (5%)(87) or 6q (9%) (88). In 
hyperplasias gain of complete or partial chromosome 17q is the most common 
chromosomal alteration. In hyperplasias similar chromosomal abnormalities to those in 
adenomas (e.i., gain of chromosome 17q), provides evidence that hyperplasias may evolve 
into adenomas (88). The hyperplasia-adenoma transition is also supported by clinical 
observation of adenomas presence within hyperplasias like PPNAD (89). In contrasts to 
benign adrenocortical neoplasms multiple chromosomal alterations in nearly all ACCs is 
observed (86-88, 90). In addition to deletions or amplifications, a high percentage of ACC 
cells exhibit loss of heterozygosity (LOH) at key loci which can result in an altered TP53 
pathway of unipaternal disomy (UPD) causing IGF2 overexpresssion.   
In adrenocortical tumourogenesis, only β-catenin mutations are found commonly in 
both benign and malignant neoplasm. In contrast, cAMP pathway genetic alterations are 
present in adrenocortical hyperplasias and some adenomas while the presence of IGF2 
locus alteration is more specific to ACCs. In addition to these differing genetic alterations, 
clinically no clear progression of adenomas or hyperplasias to ACC has been observed. 
These facts support that different mechanisms lead to adrenocortical adenoma or ACC 
formation and that adenoma do not progress to malignant tumours.  
On the other hand, some evidence refutes the latter. In mice model, overexpression 
of IGF2 does not lead to tumour formation (68, 91), suggesting that it plays a role later in 
tumourogenesis and serves as a pro-proliferative factor and not as an initiating element. 
Although this remains to be proven in humans, it suggests that IGF2 overexpression which 
is seen in the majority of ACCs does not causes tumour formation and that other genetic 
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alterations are involved in ACC formation.  As mentioned earlier, somatic mutation of 
TP53 genes are found only rarely in non malignant adrenocortical neoplasm suggesting that 
these mutations may be gained during tumour progression and are not initiating events. 
Clonality status of adrenocortical tumours also suggests a multi-stage process of 
adrenocortical development. Finally, a case report described in 2003 supports the 
hypothesis of multistep adrenocortical tumourigenesis where an adrenocortical tumour had 
a central component of ACC surrounded by benign adrenocortical tissue (92). 
Unfortunately, clonal studies to determine if both parts originated from the same population 
of cells were not possible since the patient was a male. Although this is not proof of a 
multistep model it does suggest that a multistage process can occur, though rarely.  
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Section 3.  Wnt/β-catenin  signaling 
3.1 Wnt signaling pathways 
 Wnt signaling is a highly complex and versatile process leading to a multitude of 
cellular effects. Wnt signaling is driven by a family of secreted glycoprotein called WNTS. 
Variability of Wnt effects are in part caused by the 19 different Wnt proteins present in 
humans. Wnt’s activate Wnt signaling by interaction with the frizzled family of membrane 
receptors (FZD1-10) which then activate dishevelled proteins (DVL1-3) to activate 
downstream events. There are three branches to the Wnt signaling pathway: 1) the 
canonical or Wnt/β-catenin pathway, 2) the non-canonical or the planar cell polarity 
pathway and the 3) Wnt/Ca2+ pathway.  The canonical pathway involves stabilization of β-
catenin leading to transcription activation of target genes while the other two pathways 
exert their effect independently of β-catenin. Since our studies involved Wnt/β-catenin, we 
will only briefly discuss the other two pathways. 
3.1.1 Non-canonical or planar cell polarity (PCP) signaling  
In PCP signaling (Figure 6, page 23), Wnt signaling is transduced through Frizzled 
independent of LPR5/6 (LOW density lipoprotein receptor related protein) like in the 
canonical pathway. Utilizing the PDZ and DEP protein domains of DVL, this pathway 
mediates cytoskeletal changes through activation of the small GTPases Rho and Rac 
instead of leading to β-catenin stabilization. Hence, the PCP signaling pathway controls 
tissue polarity and cell migration/movement. Aberrant activation of Wnt/PCP signaling 
pathway in human cancer (i.e.WNT5a overexpression) leads to more malignant phenotypes 
(93). This pathway is also involved in organ development (94).  
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3.1.2. The Wnt-Ca2+ pathway 
In the Wnt-Ca2+ pathway (Figure 6), Wnt signaling via Frizzled mediates activation 
of heterotrimeric G-proteins, which engage DVL, phospholipase C (PLC; not shown), 
calcium-calmodulin kinase 2 (CamK2) and protein kinase C (PKC), which modulates cell 
adhesion and motility (95). 
 
 
Figure 6: Wnt pathways independant of β-Catenin. On the left, planar cell polarity 
signaling. On the right, WNT Ca2+ signaling.(95)  
3.1.3. The Wnt/ β-catenin pathway 
   This pathway is commonly referred to as either being on (Figure 7-IB page 25), or 
off (Figure 7-IA, page 25). Normally the pathway is off, and cytosolic β‑catenin is 
constitutively degraded by the cytoplasmic degradation complex, which comprises axin, 
adenomatous polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) and casein 
kinase1 (CK1). This degradation complex triggers SCF (SKP1, Cullin, 
F‑box)/β‑TrCP‑mediated polyubiquitylation leading to proteosomal degradation of 
β‑catenin.   
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The events are triggered through phosphorylation control of the of β-catenin NH2 
terminus by multiple kinases (depicted on Figure 7II page 25). Initially β-catenin is bound 
by an Axin: APC complex. APC and Axin can be hyperphosphorylated by CK1α and 
GSK3β which increase the affinity to bind β-catenin. Once bound Axin recruits CK1α to 
the complex to phosphorylate β-catenin at serine 45 (S45). This acts a primer for further 
phosphorylation events by GSK3β at residues S37, S33, and T41. Phosphorylation of all 
four sites at the NH2 terminus are essential for proper degradation of β-catenin. APC, 
which acts as a scaffold like Axin, may also cleave the NH2 phosphorylated end and 
transfer β‑catenin to proteosomal complex (96). Ultimately the destruction complex 
maintains low levels of β-catenin when no activation signal is present. 
Upon activation, WNTs interacts with Frizzled receptors and the co-receptor 
LRP5/6. DVL proteins are activated and cause dissociation of the destruction complex and 
thus β-catenin stabilization. CK1 also synergizes with DVL to mediate this event (97). CK2 
another kinase also seems required to stabilize β-catenin by phosphorylation at residue  
T393 to inhibit  the  axin: β-catenin  interaction (98). Upon stabilization β-catenin enters 
the nucleus and acts as a transcriptional activator via interaction of with T-cell transcription 
factor family members (Figure 7I, page 25). 
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Figure 7: (I) Wnt/β-catenin pathway. a) When pathway is off β-catenins is recruited to the 
destruction complex and targeted for degradation by ubiquitin mediated proteolysis. b) When pathway is 
activated via WNT interaction with frizzled recpetors, DSH/Dvl proteins interaction with the frizzled 
receptors and inhibit recrutement of  β-catenin to the destruction complex which is termed β-catenin 
stabilization or active β-catenin. β-catenin is then exported to the nucleus and interacts with the TCF 
transcription factor and activates transcription. (II) A model depicting the β-catenin phosphorylation–
degradation cascade by the destruction complex. (a) Axin recruits CKI to phosphorylate β-catenin at S45. 
(b,c) S45 phosphorylation primes β-catenin for the succeeding GSK-3β phosphorylation cascade, finally 
hitting the S33/37 sites. (d) Phosphorylation at S33/37 creates a docking site for β-TrCP/E3RS, promoting the 
ubiquitination and degradation of β-catenin. (e) Wnt signaling, possibly through Dvl and CKI, regulates S45 
phosphorylation. Figure from Amit et al.  (99) 
  
26 
 
3.2. β-catenin 
 In humans β-catenin is a protein encoded by the CTNNB1 gene. β-catenin is  a 
member of the armadillo family of proteins. These proteins have multiple copies of the so-
called armadillo repeat domain which is specialized for protein-protein binding. 
As mentioned previously, β-catenin is the centre player of the Wnt/β-catenin 
pathway. β-catenin itself exists in three states within the cell (Figure 8). 1) Complexed 
within the destruction complex. 2) Complexed with E-cadherin and other proteins that 
constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of 
epithelial cell layers by regulating cell growth and adhesion between cells. 3) In an active 
state (unphosphorylated at S45, T41, S37, S33) where it is either in the cytoplasm or the 
nucleus bound to transcription factors such as TCF/LEF (Figure 8)  and SF1. Proper control 
of β-catenin levels and its state is essential for development and maintaining homeostasis. 
Improper control can lead to disease such as cancer (see Section 5).   
 
Figure 8: The 3 cellular states of β-catenin. Within the cell β-catenin (β) exist within three 
states; bound by Cadherins (top right), complexed with the destruction complex (axin only is shown 
here, middle), or in the nucleus. TF= TCF; β= β-catenin; P= phosphorylated residues. 
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3.2.1. β-catenin in the nucleus 
β-catenin has been involved in the transcriptional control of a multitude of genes 
mainly by co-activating gene transcription with the T-cell specific transcription factor 
(TCF) family of transcription factors (TCF-1, LEF-1(formally TCF-2), TCF-3, and TCF4 
(TCF7L2). What is of great interest is that activation of genes by β-catenin/TCF is usually 
cell and context specific. TCF proteins contain a DNA binding domain but no trans-
activation domain and can therefore not drive transcription by itself. TCF serves a dual role 
as both a repressor and activator. When unbound to β-catenin, TCF is still found bound to 
WRE (WNT responsive elements)/TBE’s (TCF binding elements) were it can act as a 
repressor upon interaction with the transcriptional repressor Groucho (Figure 9, left panel). 
When β-catenin enters the nucleus, it replaces Groucho and binds TCF. β-catenin can also 
interact with  TCF that is yet unbound to DNA which then leads to DNA binding (Figure 9 
right panel).  
 
Figure 9: β‑catenin dependent gene transcription. This pathway centres on β‑catenin, 
which, together with the DNA‑binding T cell factor/lymphoid enhancer factor (TCF/LEF) family 
proteins, functions as a transcription factor to control Wnt target genes. A subset of these target 
genes are constitutively inhibited by pioneering nuclear TCF, which recruits transcriptional 
corepressors (left panel) to Wnt response elements (WREs). Once β-catenin is exported the nucleus 
it replaces TCF-bound corepressors (such as groucho; middle panel) or co-imports additional TCF 
to occupy WREs (right panel). Once bound to WREs through TCF, β‑catenin functions as a 
scaffold to recruit an auxiliary machinery of co‑activators that are involved in chromatin 
remodelling and control of RNA polymerase II to induce Wnt target gene expression.(100). 
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It is yet unclear if these two methods for the activation of β-catenin/TCF 
transcription are gene specific of or if both can occur for the expression of the same gene. 
Once bound to WREs through TCF, β-catenin functions as a scaffold to recruit an auxiliary 
machinery of co-activators that are involved in chromatin remodelling (i.e. BRG-1(101)) 
and control of RNA polymerase II to induce Wnt target gene expression.  Regulation of β-
catenin activity is quite complex inside the nucleus. In fact, there are over 25 non 
transcription factor proteins that are known to interact with β-catenin that act as either 
antagonist or agonist of its transcriptional activity (102). This supports the hypothesis that 
nuclear accumulation of β-catenin alone is not sufficient to state activity. Transcriptional 
activity hence, what genes are expressed is affected by the variation of co-factors present. 
3.2.2. Regulation of β-catenin target genes 
Multiple genes are known to be directly regulated by β-catenin/TCF (Table 3, page 
29) and the list keeps growing.  Most genes regulated by β-catenin/TCF were discovered in 
colon cancer cells. Two of the most studied genes in relation to β-catenin/TCF regulation 
have been CCND1 (CyclinD1) and AXIN2. CCND1 regulation by β-catenin/TCF was 
originally proven by reporter assays (103). Its regulation by β-catenin/TCF in colon has 
since been refuted as CyclinD1 reporter constructs do not appear to reflect endogenous 
gene regulation (104). It is still considered a target of β-catenin/TCF activity although 
caution should be warranted for its use as a marker of β-catenin/TCF activity. 
 One of the highly important genes regulated by β-catenin/TCF is AXIN2. Similarly 
to Axin1, the Axin2 protein reduces β-catenin stability leading to a feedback inhibition on 
Wnt-signaling (105). AXIN2 contains the most known TCF sites (6 in the first intron  and 2 
in the 5’flanking site) (105) and is suggested by leaders in the WNT field, to be the most 
29 
 
conserved gene to determine activation of Wnt/β-catenin signaling between different cell 
types and signals (100, 105).  Its regulation by β-catenin/TCF differs in that it contains TCF 
binding sequences (n=6) within the first intron, while other genes, CCND1, MYC and 
ENC1 which are likely to be non universal targets, contain sites only within the 5’ flanking 
region of the transcriptional start site (103, 106, 107). 
Table III: Genes that are upregulated  directly by β-catenin/TCF  in Humans 
 Genes  Tissues/cell lines  References 
c-myc  Colon cancer He, Sparks et al. 1998)(106) 
Cyclin D              Colon cancer Tetsu and McCormick 1999) (103) 
 Tcf-1 Colon cancer Tetsu and McCormick 1999 (103) 
 PPARdelta Colon cancer He, Chan et al. 1999(108) 
 c-jun Colon cancer Mann, Gelos et al. 1999 (108)  
 fra-1 Colon cancer  Mann, Gelos et al. 1999) (108) 
MMP-7 Colon cancer Brabletz, Jung et al. 1999 (109) 
CD44 Colon cancer Wielenga, Smits et al. 1999 (110) 
Gastrin Colon cancer Koh, Bulitta et al. 2000 (111) 
ENC-1 Colon cancer  Fujita, Furukawa et al. 2001 (107) 
Claudin-1 Colon cancer Miwa, Furuse et al. 2001) (112) 
Id2 colon cancer Rockman, Currie et al. 2001 (113) 
Axin-2 Colon cancer Yan, Wiesmann et al. 2001; Lustig, Jerchow et al. 2002 
(105, 114) 
ITF-2 Colon cancer Kolligs, Nieman et al. 2002 (115) 
Nr-CAM Colon cancer  Conacci-Sorrell, Ben-Yedidia et al. 2002 (116) 
BMP4 Colon cancer Kim, Crooks et al. 2002 (117) 
Frizzled 7 EC cells Willert, Epping et al. 2002 (118) 
LEF1 Colon cancer Filali, Cheng et al. 2002 (119) 
Follistatin EC cells, ovary Willert, Epping et al. 2002 (118) 
FGF18 Colon cancer Shimokawa, Furukawa et al. 2003 (120) 
c-myc binding 
protein 
Colon cancer Jung and Kim 2005 (121) 
LGR5/GPR49 Intestine Barker, van Es et al. 2007 (122) 
Gene list was obtained from http://www.stanford.edu/~rnusse/wntwindow.html (WNT homepage). 
Only genes with substantial evidence for implication of β-catenin in their transcription are 
described.    
It is now well recognized that β-catenin target genes are cell specific. The use of 
microarray technology for transcriptome studies highly strengthens this point. Microarray 
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studies comparing gene expression profile of wild-type and tissues carrying β-catenin 
mutations in Wilms tumours (123, 124) and ovarian endometrioid adenocarcinomas (125) 
have shown a very different list of deregulated genes in comparison to table III (page 29). 
Two different studies of Wilms tumours (123, 124) even showed significant differences 
despite large cohorts studied (n=36, n=73 respectively). 
Transcriptome studies have also highlighted differences in response to WNT 
molecules from different cells.  In a study by Railo et al. (126), it was shown that upon 
WNT3a stimulation in mice NIH3T3 and rat PC12, only the expression of two genes were 
commonly activated and that only one (Disabled-2) was a direct target.  The common target 
cyclinD1 (CCND1) was not observed to be activated by WNT3a in this study although 
cyclinD1 upregulation by WNT3A was demonstrated in human embryonic carcinoma cells 
(118). In another study with mice immature CD34+ thymocytes (127), only four genes were 
commonly activated between three methods to activate Wnt signaling; WNT3a stimulation, 
expression of a constitutive β-catenin mutant and inhibition of GSK3-β by lithium. This 
demonstrated that different methods of β-catenin activation lead to unique transcriptional 
effects. There are presently, three types of control of β-catenin gene expression, 
hypothesized.  
1) Alternative isoforms of TCF: Alternative splicing of TCF7L2 (TCF4) often occurs and 
as shown in neonatal mice tissues these various transcripts lead to different gene promoter 
activation (128). In the mice developing pituitary gland, a TCF variant without DNA 
binding domain (TCF-4N) is expressed and reduces transcription of TCF/LEF dependent 
promoters by binding to β-catenin. Furthermore, TCF-4N redirects β-catenin, to activate 
non TCF/LEF dependent promoters by interaction with SF1 and the adipogenic 
transcription factor CCAAT/enhancer binding protein α (C/EBPα) (129).  What controls the 
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expression of variants involved remains unknown, but it does appear that variants of TCF 
can be expressed at key times especially during developing to alter β-catenin target genes.   
 
2) Nuclear antagonist: There exists several antagonist of β-catenin TCF transcriptional 
activity such as Chibby and ICAT proteins that appear to have a dedicated role in 
disrupting β-catenin interactions with TCF and promoting its nuclear export (130, 131).   
Other transcription factors such as members of the FOXO family or the vitamin D receptor 
can bind β-catenin which consequently inhibits β-catenin/TCF driven transcription (132, 
133). For more details on β-catenin interaction with transcription factors, please see section 
3.2.3. 
 
3) Post translation modification of TCF. Post translation modification such as acetylation, 
phosphorylation, sumoylation, and ubiquitination/degradation of TCF family members can 
also occur and can either alter β-catenin/TCF transcription in an agonistic or antagonistic 
fashion (134, 135).   
 These factors are in part responsible for the variations of genes expression mediated 
by β-catenin but these factors cannot fully explain the observation made. Cell specific 
factors determining the variability seen in β-catenin target genes remain to be determined. 
3.2.3. β-catenin transcription factors and alternative activation  
Throughout literature the main interest in β-catenin driven gene transcription is with 
the transcription factor TCF/LEF. It is now clear that β-catenin can interact with a 
multitude of other transcription factors.  Therefore, TCF proteins compete with several 
other transcription factors to bind to the limited pool of β-catenin in the nucleus (table IV).  
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Further regulatory pathways must be present in order to maintain balance, as interactions of 
β-catenin with other transcription factors leads to quite specific effects. Regulation  of these 
pathways is not fully understood and beyond the scope of this review,  but it is important to 
highlight that transcription factors other than TCF may interact with β-catenin (Table IV ) 
to understand the complexities of  β-catenin’s roles.  
Table IV: Transcription factors other than TCF family members that may use β-
catenin as a co-activator or co-repressor. 
Transcriptional 
Factors 
Effect on  
β-
catenin/ 
TCF 
Role of β-catenin References 
AR(androgen 
receptor) 
- Enhances AR transcriptional activity in 
prostate cancer  in response to 
androgens 
Truica, Byers et al. 2000 (136); 
Yang, Li et al. 2002 (137) 
ERα + Cross-talk between Wnt and estrogen 
signaling pathways  via functional 
interaction between β-catenin and Erα 
Kouzmenko, Takeyama et al. 2004 
(138) 
Foxo3a, 
Foxo1,Foxo4 
-  Stress response Essers, de Vries-Smits et al. 2005 
(139); Hoogeboom, Essers et al. 
2008 (132) 
HIF1a  - Enhance HIF-1-mediated transcription, 
promoting cell survival and adaptation 
to hypoxia 
Kaidi, Williams et al. 2007 (140) 
c-Jun +  Tumour development.  c-Jun and TCF4 
cooperatively activated the c-jun 
promoter in reporter assays in a β-
catenin-dependent manner. 
Nateri, Spencer-Dene et al. 2005 
(141) 
Mitf  - Self-renewal and maintenance of 
melanocyte stem cells, Activate 
transcription of Mitf-specific target 
promoters. 
Schepsky, Bruser et al. 2006 (142) 
MyoD  UNK Essentiel for MyoD transcription which 
is a  Transcription factor essential for 
muscle differentiation  
Kim, Neiswender et al. 2008 (143) 
p50  UNK Inflammatory response. Acts with p50 
to activate CRP expression  
Choi, Hur et al. 2007(144) 
Pitx2  + Activation of specific cell cycle gene . 
Activates CylinD1 and cyclinD2 with 
and without LEF respectively 
Kioussi, Briata et al. 2002 (145) 
Prop1  + and - Activates PIT1 (critical lineage-
determining transcription factor,) 
expression, Supresses Hesx1 (lineage-
inhibiting transcription factor) 
Olson, Tollkuhn et al. 2006 (146) 
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RAR - The activity of RA on RAR-responsive 
promoters was also potentiated by β-
catenin. RA influences development, 
cell differentiation and cancer 
Easwaran, Pishvaian et al. 1999 
(147) 
Runx2 - Control  development and maturation.  
Enhances LEF1-dependent repression of 
Runx2 
Kahler and Westendorf 2003 (148) 
Sox9  - Control of  chondrocyte differentiation Akiyama, Lyons et al. 2004 (149) 
VDR vitamine D 
receptor 
- Enhances VDR activity. Involved in 
differentiation. 
 Palmer, Gonzalez-Sancho et al. 
2001 (133) 
Steroidogenic 
factor 1 (SF1) 
UNK Hormone producing cells only, 
Synergies SF1 driven expression of 
StAR 
(Hossain and Saunders 2003 (150); 
Kim, Reuter et al. 2008 (151) 
 
Alternative transcription factors (non TCF) that are associated with β-catenin can be 
divided into two main groups. 1)  Factors that lead to redirection of β-catenin resulting in 
decreased β-catenin/TCF transcription such as RAR, FOXO and AR. 2). Factors leading to 
increased β-catenin/TCF transcription such as c-jun, SF1, and PITX2. Both groups of 
transcription factors also lead to activation of other genes which are not direct TCF targets. 
Note that the interaction with SF1 has been observed with both decrease and increase in β-
catenin/TCF transcription (150, 151).   
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Section 4.  WNT implications in normal adrenal function and 
development 
4.1. WNT in the adult adrenal gland 
 Wnt/β-catenin signaling has been poorly studied in the normal adrenal gland 
function with little to no direct studies of the players involved in this pathway. In the 
normal adrenal gland β-catenin the central player of the pathway is restricted in location 
and activity to the outer cortex (capsule and ZG) (152-154). In 2003, Suwa et al., reported 
that DKK3 an agonist of WNT pathway and WNT4 expression was much higher in the 
ZF/ZG cells then in ZR cells (155). Further study of Wnt pathway demonstrated that 
FZD1,2, DVL 3 were also expressed in the adrenal cortex but other WNTs, FZDs, and 
DVL were not expressed at the mRNA levels. WNT4 is known to be a non transforming 
WNT (156)  which means that it does lead to accumulation of β-catenin. In fact it has been 
recently shown that WNT4 redirects β-catenin to the cell membrane and thus inhibits β-
catenin/TCF transcriptional activity (157). In human pituitary adenomas, WNT4 plays a 
role in cell survival/proliferation independently of β-catenin (158). This suggests that 
WNT4 expression may help to reduce levels of β-catenin transcriptional activity in the 
adrenal gland even upon activation by other WNT ligands. Furthermore, in vitro studies 
have demonstrated that WNT4 antagonizes the interaction between SF-1 and β-catenin 
which halts the synergistic activation of the StAR (159). In normal adrenal glands, it would 
thus appear that basal Wnt/β-catenin signaling is quite low but that the adrenal cortex cells 
can respond to WNT signals due to expression or the Wnt/β-catenin pathway proteins. In 
adults, adrenal cortex effects of WNT signaling and β-catenin driven transcription are 
largely unknown, however some studies have linked this pathway to steroidogenesis both in 
a canonical and non canonical fashion (151, 160-162). 
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4.2. WNT signaling in adrenal steroidogenesis 
 Wnt signaling also plays a role in adrenal steroidogenesis.  Of the WNTs expressed 
in the adrenal gland, WNT4 has been linked to aldosterone synthesis. The initial evidence 
of involvement of WNT4 in adrenal glands was demonstrated by knock out studies of 
WNT4 that lead to a normally apparent  adrenal gland (size and shape) but with an 
abnormal ZG associated with  lower aldosterone levels (160). WNT4 overexpression in 
primary adrenocortical cells, stimulates production of aldosterone by increasing 
transcriptional levels  of the enzymes CYP17, CYP21 (in a cAMP independent manner) 
and, CYP11B2 (aldosterone synthase) (163). Furthermore, WNT4 expression in the adrenal 
gland is stimulated by cAMP, ACTH, and slightly by AngII (161).  
As discussed earlier in section 3.2.3, β-catenin can directly interact with several 
transcription factors including the steroidegenic factor-1(SF-1) (150). Studies of adipocytes 
effects on adrenal glands demonstrated that fat cells conditioned medium (FCCM) 
containing WNT10b and WNT3a, stimulated WNT transcriptional activity (β-cat/TCF 
activity) and StAR promoter in the adrenocortical cancer cell line H295R. In addition, 
cortisol and aldosterone secretion was stimulated (162). Overexpression of β-catenin levels 
(without FCCM) lead to similar effects on hormone production and was apparently 
synergistic with SF1. This study overexpressed β-catenin with an activating mutation 
(Serine45 deletion) in the H295R cells to determine β-catenin effects on StAR, SF-1 
activity and aldosterone, cortisol secretion. However, it is now well known that the H295R 
cells carry a S45P (Serine 45 to proline) mutation in the exon 3 of β-catenin gene (153, 
164) which lead to intrinsic constitutive activation of β-catenin (164) and its cytoplasmic 
and nuclear accumulation (personal observations). Moreover, this study showed no direct 
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evidence of altered β-catenin stability a hallmark of Wnt/β-catenin activation. Very 
recently, Berthon et al (152), demonstrated that constitutive activation of β-catenin in the 
adrenal cortex of transgenic mice resulted in adrenal hyperplasia as well as dysplasia of the 
cortex and medulla. Over a 17 month time period, transgenic adrenals developed malignant 
characteristics and primary hyperaldosteronism. Interestingly, the hyperaldosteronism 
observed did not involve increased expression of StAR or CYP11B2 mRNA levels but 
protein levels of CYP11B2 were increased, suggesting post translational effects. Several 
types of stabilizing β-catenin mutations in humans (see section 5.2.1 table VII) are found in 
non-secreting as well as cortisol and aldosterone secreting adenomas and carcinomas (153, 
164). 
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Figure 10: WNT/β-catenin in adrenal function.  
Figure 10 illustrates Wnt-actions in adrenocortical cells. A) On one hand, adipocyte-
derived Wnt10b and Wnt3a can induce canonical Wnt-signaling in adrenocortical cells 
which can stimulate steroidogenesis causing an increase in aldosterone and cortisol levels. 
WNT10b and WNT3a bind to frizzled receptors which lead to disassembly of the 
destruction complex and β-catenin accumulation and nuclear export. Once inside the 
nucleus β-catenin interacts with SF1 to increase StAR production thus increasing 
steroidogenesis.  TCF/LEF transcription has also been proposed to be activated but to 
unknown effects. There is also the possibility of β-catenin interaction with other 
transcription factors leading to other cellular effects.  B) On the other hand WNT4 which 
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regulates aldosterone synthesis by increasing CY11B2 (aldosterone synthase) via an 
unknown mechanism though frizzled interaction. It is yet unknown if WNT4 can activate 
canonical WNT signaling but WNT4 does block SF-1 β-catenin association. C) 
Constitutive activation of the cAMP protein kinase A pathway promotes β-catenin 
stabilization although transient effects are unknown. PKA alpha activation via bromo-8-
cAMP also increases WNT4 levels along with ACTH although through these types of 
activation direct cell effects were not determined. 
 Recent evidence has shown that 1alpha, 25-dihydroxyvitamin D(3) suppresses 
levels of corticosterone and aldosterone in the H295R cell line(165). 1alpha, 25-
dihydroxyvitamin D3 can also inhibit nuclear translocation of β-catenin.(166).  Whether or 
not, 1alpha, 25-dihydroxyvitamin D3 effects β-catenin to cause this effect on steroid 
production is unknown.  
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4.3. Wnt/β-catenin in adrenal development 
Although the involvement of Wnt/β-catenin signaling is well known in development 
its role in the development of the adrenal gland has been described only recently. Initial 
studies were in WNT4 knockout mice where decreased aldosterone secretion was observed 
with abnormal formation of the ZG. Mice after 18 weeks could not survive due to 
aldosterone deficiency. Whereas, β-catenin levels were not described in this study, thus the 
effects of WNT4 on β-catenin levels remain unknown.   
Unlike what is found in the adult adrenal gland, nuclear β-catenin is observed at 
varying times during human adrenal gland development (table V). The variability of levels 
suggests that β-catenin plays a role in the control of adrenal development. 
Table V: Nuclear β-catenin immunoreactivity  in adrenal development 
 10-15 
weeks 
(n=2) 
16-18 
weeks 
(n=2) 
22 weeks 35weeks 1.5 years 44 years 
Adrenal - +h - ++h ++h +/-i
h Outer cortex, i Glomerulosa cells. Table modified form Charles Eberhart, C,G and Argani (154) 
Later studies showed that disruption of β-catenin driven by the Sf1/Crehigh 
transgene causes the complete absence of adrenal glands in mice (151). This effect was 
different than that seen in WNT4 KO mice (160) perhaps owing to potential roles of WNT4 
in noncanonical Wnt signaling (158, 167, 168) and to the activation of the canonical 
pathway in the adrenal gland by additional Wnt ligands, or to Wnt-independent actions of 
β-catenin.  Furthermore, mice with Sf1/Crelow-mediated β-catenin KO (n=4) exhibited 
histological disorganization and thinning of the adrenal cortex by 45 weeks (151). These 
experiments demonstrated requirement of β-catenin in mouse adrenal development and 
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places β-catenin in a small group of transcriptional regulators, which includes Sf1, Dax1, 
Wt1 Pbx1 and Cited2, to which deficiency causes complete adrenal absence (151). 
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Section 5.  Wnt/β-catenin in adrenal tumourogenesis  
5.1. Wnt/β-catenin signaling alterations in cancers 
 Over the last decade Wnt signaling has been found to be increasingly important in 
cancer and as such has been under extensive study to understand its implication in cancer 
development and tumour maintenance. Wnt/β-catenin signaling alterations have been found 
to some extent in almost all cancers studied. Alterations leading to uncontrolled regulation 
of Wnt/β-catenin are caused in three ways (see figure 11 for diagram). 
 
Figure 11: Common causes of Wnt signaling aberrant activation in cancer cells. (A) 
Mutations in APC or axin 1 genes causing expression of truncated protein. (B) Mutation of the 
conserved serine/threonine phosphorylation sites at the amino terminus of β-catenin blocks its 
phosphorylation within the destruction complex, allowing accumulation of β-catenin and formation 
of an active transcription factor complexes with Tcf/Lef in the nucleus. (C) Loss of natural Wnt 
inhibitors such as SFRP or WIF through epigenetic silencing of the corresponding genes allows 
Wnt proteins produced by the cancer cells to activate the pathway at the membrane. (169) 
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A) Mutations of axin or APC genes leading to absence of binding of β-catenin. β-catenin 
remains free of the destruction complex leading to constitutive activity of  β-catenin.   
B) Mutations of exon 3 of β-catenin gene coding for serine/threonine residues which are 
normally phosphorylated. The mutations lead to alterated phosphorylation of β-catenin and 
constitutive activity of β-catenin as well. Although mutations in each of the components of 
the complex may cause abnormal cytosolic stabilization of β-catenin, mutations of the β-
catenin gene itself appear to be the most common cause of stabilization of pathological 
situations. These mutations predominantly affect residues at positions Ser33, Ser37, Thr41 
or Ser45 (Figure 12) located in exon3 of the human β-catenin gene that are the targets of 
priming phosphorylation by CKIα (S45) or subsequent phosphorylation by GSK3β (S33, 
S37 and T41). The other mutations (Figure 12) that have been found are thought to affect 
the recognition sites of the enzymes that regulate β-catenin. However, it is yet unclear if 
these mutations lead to β-catenin constitutive activity. 
 
Figure 12 : Mutations of exon 3 of β-catenin in the literature. A) Graph showing 
thespectrum of β-catenin mutations in human malignant tumors Only amino acids reported 
as mutated more than five time in the literature were included. Ser37, Thr41, Ser45, Asp32, 
Ser33, and Gly34 were identified as the more prevalent mutations. B) Spectrum of 
mutations in benign tumors. The same six mutations were dominant, but in a different order 
of frequency: Ser37, Ser33, Asp32, Thr41, Gly34, and Ser45. The only other mutations 
identified in benign lesions were Ile35 (two cases) and Ala43 (two cases). Figure from 
(170). 
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 C)  Although less common, loss of SFRP or WIF proteins which normally inhibit WNT 
molecules can also lead to constitutive activity of β-catenin. 
Activation of β-catenin finally leads to transcriptional activation of various genes 
(Table III, page 29). Up to now, in the literature the role of these genes in tumor 
development remains mainly speculative, although the predominant mutations lead to 
increased stability of β-catenin, the downstream effects may vary. Thus implications of β-
catenin may also change depending on the alterations of the pathway present. In a study 
performed in MDCK cell line, cells were transfected with β-catenin S45, 37, 33 and T41 
mutants (170). All mutants contained some level of transforming ability but mutations did 
lead to varying cellular effects. Transcription of cyclinD1/CCND1 was also increased but 
only with the S45 mutant (170). Studies of two non serine/threonine mutations (Asp32 and 
Gly34) in MCDK cells demonstrated that only the Asp32 mutation had cell transformation 
potential but this mutation did alter expression of the genes normally activated by β-catenin 
such as CCND1 (171). Another study in Hek293 cells demonstrated using reporter assays 
that transfection of Asp32 substitution mutations (D32G, D32N and D32Y) activated β-
catenin/TCF transcriptional activity (172). However, expression of specific genes were not 
reported in this study. Furthermore, they also showed that various types of substitutions of 
D32 differentially affect efficiency of β-catenin phosphorylation at serine33 with D32Y 
showing the greatest reduction. Interestingly, there were no differences in β-catenin 
stability between the different substitutions (172). 
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5.2. Implication of Wnt signaling alterations in adrenal tumors.   
Although most cases of adrenocortical lesions are sporadic a small percentage may 
be associated with hereditary syndromes such as familial adenomatous polyposis (FAP). 
FAP is primarily associated with high risk of colon cancer. In 1997, Marchesa et al., 
reported that patients with FAP more frequently developed adrenal tumors (7.4%)  in 
comparison to the general population (0.6%-3%) (173). In an another study, the prevalence 
of adrenal masses in 107 FAP patients was 13% (174). Patients with FAP carry a germline 
mutation in APC, which can lead to constitutive activation of β-catenin (175, 176), and 
increased levels of β-catenin/TCF target genes (177). Most adrenal masses in FAP patient 
are benign. In 2000, a first study was interested into the possibility of Wnt/β-catenin 
alterations in adrenocortical tumors. A cohort of 26 adrenocortical tumours, 13 
neuroblastoma and 12 pheochromocytomas was studied however any nuclear accumulation 
of β-catenin was found thus no genetic alterations of β-catenin were searched (178).  
Following this work, several transcriptome studies using microarray technology have 
demonstrated aberrant expression of several genes known to be regulated by Wnt/β-catenin 
in adrenocortical tumors (summarized in table V1, page 45). Gene array analysis of 
macrodular adrenal hyperplasia (AIMAH) by Bourdeau et al., demonstrated that WISP2 
and connexin43 were up-regulated in GIP-dependant AIMAH (179). Both the expression of 
WISP2 and connexin43 are known to be regulated by β-catenin (180, 181). Serial analysis 
of gene expression (SAGE) analysis of PPNADs with PRKAR1A inactivating mutations  
also revealed overexpression of multiple genes implicated in Wnt pathway (see table V1, 
page 45) (182). However the latter includes negative regulators such as AXIN1 and GSK3β 
which could inhibit additional effects provided by overexpression of CTNNB1 or DVL2.   
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Giordano et al., reported aberrant expression of ENC1 and TOP2A (62) in ACCs.  ENC1   
is regulated by β-catenin/TCF in Lovo cells (colon cancer cells) and may contribute to 
colorectal carcinogenesis by suppressing colonic cells differentiation (107). The TOP2A 
gene codes for topoisomerase IIα. Topoisomerase IIα is recruited by β-catenin and acts as a 
transcriptional enhancer (183). Studies have shown that overexpresing of β-catenin 
increased catalytic activity of Topoisomerase IIα and that overexpression of Topoisomerase 
IIα increases β-catenin/TCF transcriptional activity (183). It is therefore plausible that in 
ACC, increased TOP2A, could contribute to the high amount of cases with β-catenin 
accumulation which are not accounted by presence of mutations (section 5.2.2, Figure 13, 
page 48)  
 
Table VI: Deregulation of Wnt signaling/target genes in adrenocortical  
Genes Type of 
study/diseases 
Deregulation Validated by real-
time PCR 
References 
TOP2A, ENC1 Microarray study of 
ACC vs normal and 
ACA 
Upregulated in 
ACC 
Validated (TOP2A only) Giordano, Thomas et al. 2003. (62) 
Connexin43, 
WISP2 
AIMAH Upregulated in 
AIMAH 
Validated (WISP2 only) Bourdeau, Isabelle et al. 2004. 
(179) 
DVL2, Axin1, 
CTNNB1, 
CSNK1E, GSK3β, 
CTNNAL1, 
WISP2 
SAGE analysis of 
PPNAD vs normal 
adrenal gland 
Upregulated in 
PPNAD 
 
Unvalidated Horvath, Mathyakina et al. 
2006.(182) 
WNT4, TOP2A Microarray study 
of pediatric  ACC 
Downregulated in 
children ACT's 
Validated (TOP2A only) West, Neale et al. 2007.(184) 
WISP2 MiRNA array 
study of PPNAD.'S 
Upregulated in 
PPNAD 
Validated Iliopoulos, Bimpaki et al. 2009. 
(185) 
APC ACC vs ACA Upregulated in 
ACC 
Not validated Laurell, Ceilia et al.2009. (186) 
ENC1, TOP2A ACC vs ACA and 
NA 
Upregualted in 
ACC 
Not validated Giordano, Thomas et al. 
2009.(187) 
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5.2.1. Implication of β-catenin mutations 
  Currently β-catenin mutations are the most frequent genetic alteration found in both 
sporadic adrenocortical adenomas and ACC. Our laboratory reported for the first time the 
presence of β-catenin mutations in adrenocortical adenomas at the 55th ASHG Annual 
Meeting (188) which was published in 2008 (89). Similarly, Tissier et al (164) reported the 
presence of beta-catenin mutations in 7 out of 26 (27%) adrenocortical adenomas and 4 out 
of 13 adrenocortical carcinomas (30%). We found similar results in a cohort of 33 
adrenocortical adenomas (5/33) 15% but did not find any beta-catenin mutation in ACC, 
although only four samples were studied (89). Sixteen ACTH independent hyperplasia’s 
were not found to carry any β-catenin mutation in this study.  Both of latter studies also 
found an S45P mutation in the human adrenocortical cancer cell line H295R which was 
shown to activate β-catenin/TCF transcription (164). A third study by Masi et al (189) also 
found  mutations in 3 of 15 (20%) ACCs and in 8 of 41 (19.5%) adrenocortical adenomas.  
Most β-catenin mutations are present at the critical serine and tyrosine residues of exon3 of 
the β-catenin gene which leads to cytoplasmic and nuclear accumulation of β-catenin.  In 
accordance to the nature of the mutations all mutants were found to have elevated nuclear 
and cytoplasmic levels of β-catenin suggestive of constitutive β-catenin activity. Note that 
immunohistochemistry to localize β-catenin was not performed in the study by Masi et al 
(189). All mutations found in adrenal tumours are summarized in table VII (page 47). 
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Table VII: Summary of β-catenin mutations found in adrenocortical tumors 
Studies Adenomas Carcinomas PPNAD 
 Prevalenc
e % 
Mutations (n : 
number of cases) 
% 
Prevalence 
Mutations(n : 
number of 
cases) 
% 
Prevalence 
Mutations(n : 
number of 
cases) 
Tissier et al, 
2005.(164) 
7/26 
(26,9%) 
S45P (n : 3);       
S45Y (n : 1);       
S45F (n : 1);       
26,813 del 376 bp   
(n : 1);         
DinsS33S(n : 1) 
4/13 (30,8%) S45F (n :1);   
del S45 (n :1); 
T41A (n :1); 
26,993 del 489 
bp(n :1) 
 
  
Tadjine et 
al, 
2008.(153) 
 
5/33 
(15%) 
S37C (n : 1);       
S45F (n : 1) ;       
26 943 del55 bp 
(n : 1);            
27 127 del6 bp 
(n : 1);  26 995 
del271 bp(n :1) 
0/4 (0%)    
Tadjine et 
al, 2008.(89) 
    2/18 
(11,1%) 
T41A (n :1)      
S45P (n :1) 
Gaujoux et 
al, 2008. 
(190) 
1/3 
(33,3%) 
S45F (n :1) 1/1 (100%)* p.Tyr30X (n :1) 2/9 (22%) c.236_349 
191del304 
(n :1) 
T41A (n :1) 
Masi G et 
al, 2009. 
(189) 
8/41 
(19,5%) 
S45P (n : 5); 
P44A  + S45P 
(n :2) ;    
A43_R53Del 
(n:1) 
3/15 (20%) H36P (n :1) ; 
T41P (n :1); 
D32H (n :1) 
  
Pusantisamp
an T, 2010. 
(191) 
  
 
1/1 
Childhood 
ACC * 
Del S45   
Prevalence 
of mutations 
21/103 
(20%) 
 7/32  (20%)  4/27  
*This case study was not included in the calcul of total prevalence. 
  
In total 32 β-catenin mutations in adrenal disorders have been reported and 19 of 
them (59%) involved some alteration affecting the serine 45 residue. Both Tissier et al 
(164) and Tadjine et al (89) studies also revealed elevated β-catenin levels in tumors with 
no β-catenin mutations. This suggests that other factors of the Wnt/β-catenin may be 
affected. This is mainly observed in ACC where 75% of the tumours showed β-catenin 
accumulation (164, and personal observations). This is in accordance with the 
48 
 
overexpression of ENC1 seen in the majority of ACCs. Aberrant nuclear localization of β-
catenin without genetic alterations in CTNNB1 or AXIN genes was also found in 
oesophageal cancer (192). Mutations in pigmented nodular adrenocortical disease 
(PPNAD) have also been found in 2 of 18 (89, 193) and 2 of 9 (190) cases studied.  
Mutation status in APC was also studied in our laboratory but no mutants were found 
(unpublished results). The total amount of CTNNB1 mutations and observation of β-catenin 
accumulation are graphically represented in figure 13 (page 49). 
 
Figure 13: Summary of β-catenin mutations and aberrant accumulation of beta-
catenin in adrenocortical diseases. AA= adrenocortical adenomas (21 mutations out of 103). 
ACC=adrenocortical carcinomas (7 mutations out of 32). AIMAH=ACTH independent 
macronodular adrenocortical hyperplasia (0 mutations out of 13, unpublished data). PPNAD= 
primary pigmented nodular adrenocortical disease (4 mutations out of 27). Data from (89, 
164),(153, 190). Note at this time data is insufficient to correlate mutation type to adrenal tumour 
type. 
5.2.2. Wnt/ β-catenin   and cAMP pathway cross talk 
In a study by Gaujoux et al, patients carrying a germline genetic alterations of  the 
type 1-α-regulatory subunit of cAMP-dependent protein kinase A (PRKAR1A) had 
abnormal β-catenin accumulation in their PPNAD tissues (190). These mutations cause 
abnormal activity of PKA which alters cAMP cellular levels. Therefore the cAMP pathway 
in the adrenal may also regulate Wnt/β-catenin signaling. It is yet unproven in this context  
but protein kinase A (PKA) has been shown  to directly phosphorylate β-catenin at S675 in 
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vitro and promote its stability by inhibiting its ubiquination in L cells and Hek-293 cells 
(194) leading to increased cell proliferation (195). In accordance to the increased β-catenin 
levels observed in PPNAD, especially in those with PRKAR1A mutations (190), several 
genes implicated in WNT signaling are overexpressed in PPNAD (see section 5.2.1).  A 
microRNA (miRNA) profiling study in PPNAD’s by miRNA array comparative analysis 
demonstrated that WISP2, like in GIP dependant-AIMAH is up-regulated, due to 
downregulation of miR449 (185). PKA activity was directly shown to affect MiR449 levels 
(185). Therefore PKA may also affect the Wnt signaling pathway, by regulation of 
miRNA’s. 
5.2.3. Model of β-catenin driven adrenal tumourogenesis 
 Steps involved in tumor development in adrenocortical tumourogenesis are still 
under extensive study. Moreover, progress has been slow in part to the rare prevalence of 
ACC. Up to now there is no direct evidence of progression of adrenocortical adenomas to 
ACC. The main recognised hypothesis is that ACC is a separate identity then adenomas and 
hyperplasias. β-catenin mutations are to date the only mutations found commonly  in ACC 
as well as in adenomas. This is suggestive that β-catenin could be involved in 
adrenocortical tumour progression. Studies from mice expressing β-catenin with a 
stabilizing mutation specifically in the adrenal gland, have shown that this mutation causes 
aldosterone producing hyperplasias as well as dysplasia of the cortex and medulla (152). 
After 17 months expression of the mutants can lead to the presence of malignant tumors 
(152).  This evidence is highly suggestive that not only β-catenin is involved in tumor 
progression but that ACC can evolve from hyperplasias. In this study β-catenin/TCF 
transcription was confirmed to occur by observation of moderate (1.5fold) AXIN2 
overexpression in adrenal tumors expressing the β-catenin mutations. Mechanistically it is 
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still unclear on how β-catenin triggers/participate in malignant tumor formation. Gene 
targets of β-catenin transcriptional activity in adrenal gland and its associated tumors 
remain unknown and therefore it not yet possible to determine how β-catenin mutations 
alter the transcriptome to cause tumor progression. Transcriptome of malignant and benign 
adrenocortical tumors clearly differ (62, 63) but this is based on evidence which does not 
consider β-catenin mutational status. The actual difference between the transcriptome of 
benign and malignant tumors with WNT/β-catenin signaling alterations remains unknown. 
β-catenin mutations have been associated with  genomic instability in colon cancer (196) 
and hepatocellular carcinomas (197). Therefore β-catenin mutations could also possibly 
cause the increase in genomic instability observed from hyperplasia to adenoma to ACC in 
a subset of tumors, but this remains speculative. In other models such as colon cancer, β-
catenin mutations are not considered sufficient to cause malignancy therefore a secondary 
event such as chromosome alteration/mutations are required. In ACC, genetic events such 
as overexpression of IGF2 or TP53 alterations would be essential for the development of 
malignancy and or to accelerate tumor formation. The prevalence of somatic β-catenin 
mutations in ACC carrying TP53 (somatic or germline) mutations remains to be 
determined. While IGF2 overexpression is wide spread in ACC and surely occurs in 
presence or absence of Wnt/ β-catenin signaling alterations.   
5.3. β-catenin and human Adrenocortical cell lines.  
Permanent and stable cell lines are of great importance in molecular biology and 
scientific research in general.  Unlike for colon or breast cancer there are few human ACC 
cell lines available with only two commercially available; the human adrenocortical 
carcinoma cell lines SW13 (ATCC# CCL-105) and H295R (ATCC# CRL-2128). Two 
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other adrenal cell lines have been generated, the human pediatric adrenocortical cancer cell 
line HAC15 and the PPNAD cell line described by Palmar et al. (198) and Iliopoulos et al 
(185) that are not commercially available.  
5.3.1. H295R cells. 
 The H295R cell line is the most commonly used and has been useful for 
defining the cellular mechanisms regulating steroid production as its produces both 
aldosterone and cortisol. In addition, H295R cells are responsive Ang2.  As mentioned 
earlier, H295R cells carry the S45P β-catenin mutation (164, 199) which leads to 
constitutive β-catenin/TCF transcriptional activity (164). This cell line also contains an 
F338L mutation in the TP53 gene (200). Treatment of H295R cells with the β-catenin/TCF 
inhibitor PKF115-584 results in decreased proliferation and increased apoptosis 
demonstrating the importance of β-catenin/TCF for H295R cell survival when the Wnt 
signaling pathway is active. 
5.3.2. SW13 cells 
 The SW13 cell line was isolated from a 55 year old female with stage IV 
adrenocortical carcinoma in 1973 (201). This cell line is non-functional (non steroid 
producing) and therefore is not often used in adrenal research. It is considered to represent a 
model of ACC much more aggressive than the ACC H295R cells. SW13 cells do not 
contain any known mutations in APC, Axin1/2, β-catenin (unpublished results) and is 
therefore considered to not have any aberrant Wnt/β-catenin activity.  It could therefore be 
thought to be a good wild-type model to study β-catenin activation. However the major 
population of SW13 do not express BRG-1 a critical factor in the SWI/SNF complex 
required in chromatin remodelling. β-catenin recruits the SWI/SNF complex via interaction 
with BRG-1 to activate expression of at least a subset of genes like CCND1.  This cell line 
52 
 
could therefore potentially represent a non WNT responsive cell line. This cell line also 
does not produce active  p53 (202).   
5.3.3. HAC15 cells 
HAC15 is a recently developed cell line in the Rainey’s laboratory from a human 
adrenocortical carcinoma (HAC) removed from an 18-month old girl presenting with 
virilization and hypertension (198). HAC15 is the first ACTH responsive cell line. 
Although very few studies with this cell line have been done, this cell line is now known to 
us to also carry a β-catenin S45P mutation such as the one found in the H295R cells 
(unpublished data). This cell line allowed us to distinguish β-catenin effects in childhood 
ACC (HAC15cell line) and adult ACC (H295R cell line).  
 
 
 
 
 
 
  
Chapter II.  Research Project 
 1. Basis for Research 
Broad application of radiological techniques have led to frequent detection of 
adrenal lesions (adenomas, hyperplasias or carcinomas) in the general population (2-3%) 
(203). Currently, there are no reliable diagnostic or prognostic markers to clinically (before 
surgery) and histologically determine the benign or malignant potential of the lesions (204, 
205). Estimation of the likelihood of malignancy is clinically important since adrenocortical 
carcinoma is an aggressive tumor and the overall 5-year survival rate is less than 40% (204, 
206, 207). Surgery is the only efficient treatment since the response to chemotherapy and 
the adrenolytic agent mitotane is poor (204). A better understanding of the molecular 
mechanisms with improved diagnostic and prognostic markers as well as treatment 
strategies is required to assist clinicians in the management of adrenocortical tumours. 
 Adrenocortical tumours and hyperplasias may be associated with familial 
syndromes: Li-Fraumeni (p53, 17p13), familial adenomatous polyposis (APC), and Carney 
complex (PRKAR1A) (15, 24) (27, 28). However, the genetic alterations remain unknown 
in most sporadic adrenocortical tumours. Using cDNA microarray analysis, studies a 
number of genes related to the Wnt/β-catenin signaling pathway have been found altered, in 
hyperplasias (AIMAH and PPNAD), adenomas and carcinomas, suggesting the 
involvement of the Wnt pathway in adrenocortical tumourigenesis ((179) and unpublished 
data).   
 The genes for β-catenin (CTNNB1),  APC, and AXIN in the Wnt signaling pathway 
are often mutated in human cancers, which results in the activation of transcription by β-
catenin (208-210). APC gene is mutated in the majority of sporadic colorectal cancers. β-
54 
 
catenin mutations also occur commonly in sporadic cancers outside of the gut such as in 
endometrioid ovarian cancer (211), hepatoblastoma (212-214) and Wilms’ kidney tumour 
(215). Wnt signaling pathway alterations are highly linked to tumor progression in cancers 
such as in the colon (216) and hepatoblastoma (217).  
  Recently β-catenin mutations have been demonstrated to be highly prevalent in 
adrenocortical hyperplasias (PPNAD only), adenomas and carcinomas (89, 153, 164, 189) 
with a prevalence of about 20% (Figure 13, page 48). β-catenin mutations are the most 
commonly found mutation in benign and malignant tumors. Studies implicating β-catenin 
in adrenal tumors have been largely descriptive and the fundamental changes brought upon 
by β-catenin mutations remains unknown. 
 The principal effects brought upon by β-catenin activation are changes in gene 
transcription. β-catenin gene targets are believed to be largely context dependant and in the 
adrenal gland gene targets and subsequent cellular effects remain unknown.   
Transcriptome studies by cDNA microarray analysis allows determination of the gene 
expression profile of all genes/transcripts from the human genome. Comparisons between 
two or more groups can therefore be performed to determine changes in gene expression 
profiles. cDNA microarray analysis  has been extensively used  in the study of adrenal 
tumors/hyperplasias in order to determine prognostic factors, specific diseases markers, and 
pathway alterations. These studies have lead to the discovery of IGF2 and TOP2A 
overexpression in ACC, WISP2 overexpression in AIMAH and others. Microarray studies 
have not been performed yet to distinguish expression profiles brought upon by changes of 
mutations in a specific gene. 
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2. Research Plan and objectives 
Due to the common occurrence of β-catenin mutations in adrenal lesions it is 
imperative to better understand the effects brought upon by these mutations. β-catenin is 
considered a legitimate cancer therapeutic target however its essential nature in normal cell 
functioning throughout the body provides certain challenges.  Genes which are abnormally 
activated by β-catenin like CCND1 and MYC have direct functional role in tumourigenesis 
(103, 106). Therefore, it is pertinent to first study the impact of the presence of β-catenin 
mutations on gene expression profile of tumours which may lead to the identification of 
new potential therapeutic targets. Taking into account that a number of genes affected by β-
catenin can most likely themselves modify expression of another set of genes, it is  
expected that total gene expression analysis of tumours harbouring β-catenin mutations 
would reveal deregulation of genes that may not be directly regulated by β-catenin. 
However, transcriptome studies may provide a global picture of transcriptional changes and 
may help to distinguish genetic changes specific to tumours with or without β-catenin 
mutations. 
 We therefore designed a microarray experiment to determine transcriptional 
differences in adenomas with known β-catenin activating mutations (n=3) and confirmed β-
catenin nuclear accumulation  compared to adrenocortical adenomas with wild-type β-
catenin gene (n=4) and no nuclear accumulation of β-catenin protein, as determined in 
Tadjine et al. 2008 (153).  Seven genes were selected for validation by real-time PCR 
analysis in an expanded cohort of adrenocortical samples (3 adenomas with β-catenin 
missense mutations, 3 adenomas with β-catenin deletion mutations, 13 Wt adenomas (5 
aldosterone-secreting adenomas and 8 cortisol-secreting adenomas), 1 ACC with β-catenin 
missense mutations, 4 Wt ACCs and 10 normal adrenal glands. Given the small number of   
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tumor harbouring  β-catenin mutations available to us, we used β-catenin/TCF inhibitors to 
treat the human adrenocortical carcinoma cell line H295R, which harbour β-catenin 
activating mutation to determine if inhibition of  β-catenin/TCF would alter expression of 
our selected genes. This allowed us to determine further links between β-catenin and 
expression of genes found in the microarray analysis.                 
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ABSTRACT 
Background. Mutations of β-catenin gene (CTNNB1) are frequent in adrenocortical 
adenomas (AA) and carcinomas (ACC). However, the target genes of the de-regulated 
Wnt/β-catenin signaling pathway have not yet been identified in adrenocortical tumours. 
Objective. To identifiy genes specifically de-regulated in adrenocortical tumours 
harbouring CTNNB1 genetic alterations.  
Methods. We compared gene expression profiles of AA with (n: 3) and without (n: 4) 
CTNNB1 mutations using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide 
arrays. The mRNA expression of 7 selected genes was validated in 6 AA with CTNNB1 
mutations, 13 AA with wild-type (WT) CTNNB1, 1 ACC with CTNNB1 mutation, and 4 
WT ACC in comparison to 10 normal adrenal glands. We then studied the effects of 
suppressing β-catenin transcriptional activity with the β-catenin/TCF (T-cell factor) 
inhibitors PKF115-584 and PNU74654 in H295R and SW13 adrenocortical cell lines. 
Results. One hundred and twenty-eight probe sets had a minimal mean expression ratio of 
2, and 407 probe sets had a mean ratio of 0.5 or less in tumours with CTNNB1 mutations 
compared to WT tumours. Real time polymerase chain reaction analysis confirmed the 
over-expression of ISM1, RALBP1 and PDE2A as well as the down-regulation of PHYHIP 
and CITED2 in 5/6 AA harbouring CTNNB1 mutations compared to WT AA (n: 13) and 
normal adrenal glands (n: 10). CDH12 and ENC1 were specifically over-expressed in AA 
harbouring CTNNB1 point mutations. mRNA expression of ISM1, RALBP1, PDE2A and 
ENC1 was decreased in a dose-dependent manner in H295R cells after treatment with the 
TCF/β-catenin  antagonists PKF115-584 and PNU74654 whereas CITED2 levels were 
increased.  
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Conclusion. This study identified new candidate genes specifically de-regulated in 
CTNNB1-mutated adrenocortical tumours that may lead to a better understanding of the 
role of Wnt-β-catenin pathway in adrenocortical tumourigenesis. 
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INTRODUCTION 
Adrenocortical tumours may be associated with familial syndromes,  however, the genetic 
alterations remain unknown in most sporadic cases (1). Recent microarray studies described 
the aberrant expression of a number of genes related to the WNT-β-catenin pathway in 
adrenocortical hyperplasias, adenomas and carcinomas (2-6).  In addition, β-catenin 
(CTNNB1) mutations were found recently in 15 to 26.9% of adrenocortical adenomas (AA) 
(7, 8, 9)  and in up to 30.8% of adrenocortical carcinomas (ACC) (7) (9).  
Wnt signaling plays a key role in development and tumourigenesis (10-13). WNT proteins 
bind to a complex containing frizzled and low-density lipoprotein receptor-associated 
proteins (LRP5/6) at the cell surface. This mobilizes signaling protein dishevelled, which, 
in turn, inhibits the activity of glycogen synthase kinase-3beta (GSK-3β). GSK-3β forms a 
complex with 2 β-catenin-binding proteins, APC, and axin (AXIN). In the absence of 
WNT’s, β-catenin is recruited into the complex which facilitate its phosphorylation by 
casein kinase 1 and activate GSK-3β, making β-catenin available for degradation (13). 
Thus, β-catenin level is normally low in the cell cytoplasm and nucleus. In contrast, 
activation of Wnt, inhibits GSK-3β activity; consequently, β-catenin accumulate and form 
complexes with T-cell factor/lymphoid enhancer factor (TCF/LEF) proteins in the nucleus.  
CTNNB1 mutations affect specific serine and threonine residues localized in exon 3 that are 
essential for the targeted degradation of β-catenin (14). Doghman et al., reported that the 
TCF/CTNNB1 antagonist PKF115-584 inhibits proliferation of H295R ACC cells (15). 
Very recently, Berthon et al. observed that constitutive activation of β-catenin in the 
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adrenal cortex of transgenic mice leads to benign aldosterone-secreting tumour 
development and promotes malignancy (16).  
When it is translocated to the nucleus, β-catenin functions as an oncogene, binding to 
TCF/LEF family members, and trans-activating its target genes. c-Myc (17) and cyclin D1 
(18) have been found to be critical TCF-regulated target genes in colon cancer. However, 
this aspect has never been explored in adrenocortical tumours. To identify candidate genes 
linked to CTNNB1 mutations in adrenocortical tumourigenesis, we investigated by 
microarray analysis the differential gene expression profiles of adrenocortical tumours with 
mutational defects in CTNNB1 gene and tumours with intact regulation of β-catenin 
activity.  
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MATERIALS AND METHODS 
Adrenocortical tissues 
We studied 34 adrenocortical tissues, including 10 normal adrenal glands (NA), 13 AA 
with wild-type (WT) CTNNB1 gene, 6 AA with CTNNB1 genetic alterations (3 harbouring 
missense mutations and 3 with deletion mutations), 4 ACC with WT CTNNB1 and 1 with 
CTNNB1 missense mutation. Adrenal glands were surgically removed from patients and  
snap frozen. A pool of commercially-available RNA (Clontech Laboratories, Palo Alto, 
CA, USA), isolated from NA of 62 Caucasian subjects aged 15-61 yr, was also studied. The 
study was approved by the Institutional Ethics Committee of Centre hospitalier de 
l’Université de Montréal (CHUM), and all patients provided informed, written consent. 
Human adrenocortical cancer cell lines 
The human adrenocortical carcinoma cell lines SW13 and H295R were obtained from the 
American Type Culture Collection (ATCC) (Manassas, VA, USA) and cultured according 
to ATCC.  H295R cells harbour an activating missense mutation in exon3 of CTNNB1 gene 
(S45P) (7, 8), along with a heterozygous F338L mutation in the TP53 gene.  
Microarray sample labelling and hybridization  
To evaluate differential gene expression related to β-catenin, we studied 3 β-catenin-
mutated tissues with point mutations showing higher translocation of nuclear β-catenin 
protein: 2 cortisol-secreting AA (S45P, S37C) and 1 aldosterone-secreting adenoma 
(T41A). The gene expression profile was compared to 3 cortisol-secreting and 1 
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aldosterone-secreting AA with WT CTNNB1 and no known nuclear accumulation of β-
catenin protein. The commercially-available pool of 60 NA described earlier served as 
control.   
Total RNA was isolated with TriZOL reagent (Invitrogen, Carlsbad, CA, USA), and all 
RNA used had RNA integrity number (RIN) values above 8 [values ranging from 10 
(totally intact) to 1 (totally degraded)]. Microarray experiments were performed with 
human expression Human Genome U133 Plus 2.0 gene chip arrays (Affymetrix, Santa 
Clara, CA, USA). Briefly, 5 µg total RNA were reverse transcribed with T7-(dT) 24 
oligonucleotide as primer, labelled with biotin, and fragmented with Affymetrix reagents. 
Ten μg of the resulting cRNA were loaded onto each chip. After washing and staining with 
streptavidin-phycoerythrin (Invitrogen), the chips were scanned with a Genechip Scanner 
3000 workstation (Affymetrix). 
Microarray data analysis and statistics  
Probe set intensity levels were extracted from scanned oligochips with the gene chip 
operating system (version 1.2, Affymetrix) and normalized with all probe sets and a target 
value of 500. For normalization, each oligochip’s dataset was centered on its median 
intensity and each probe set was normalized to control RNA. Probe sets that were 
statistically different from adenomas with CTNNB1 mutations compared to AA with WT 
CTNNB1 were identified by Student’s 2-tailed heteroscedastic t test with an alpha of 0.05. 
For up-regulated genes, we retained only probe sets flagged as present in at least 2 of the 3 
adenomas with CTNNB1 mutations. For down-regulated genes, we kept the probe sets 
flagged as present in the control and in at least 2 of the 4 WT AA. Finally, the probe sets 
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were filtered according to differences between the 2 adenoma groups represented by a 
minimum 2-fold increase in intensity.  
 
Validation of gene expression by real time-polymerase chain reaction (RT-PCR) analysis. 
To validate gene expression, RT-PCR was performed on 3 AA with CTNNB1 missense 
mutations, 3 AA with CTNNB1 deletion mutations, 13 WT AA (5 aldosterone-secreting 
adenomas and 8 cortisol-secreting adenomas), 5 ACC (4 WT and 1 with CTNNB1 S45P 
mutation), and 10 NA. One μg of RNA was processed for cDNA synthesis. PCR 
amplification mixture was prepared with Quantitect SYBR green RT-PCR kit (QIAGEN), 
and amplifications were conducted in a Rotor-Gene 6000 cycler (Corbett Research, Sydney, 
NSW, Australia). Primer sequences are described in Supplemental Table 1. An initial 
denaturation step of 5 min at 95oC was followed by 45 cycles of 95oC for 30s, 60°C for 30s 
and 72oC for 30s. Standard curves for each primer set reaction were charted to confirm 
100% efficiency and melting curve analysis was conducted. mRNA levels were normalized 
to 18S rRNA. Relative expression ratios were determined by the Pfaffl method (19) by 
normalizing expression values with the pool of commercially-available adrenal gland RNA 
(Clontech Laboratories). For each tissue sample studied, RT-PCR was repeated at least 
twice for 2  independent RNA extractions, or three times when only 1 RNA extraction was 
available. Averages were calculated for each group, and error was computed from standard 
deviation. One-way ANOVA and Bonferroni's multiple comparison test ascertained 
statistical significance with a cut off p-value of 0.05.  
Treatment of cells with antagonists of TCF4/β-catenin protein complex  
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PKF115-584, generously provided by Novartis (Basel, Switzerland), was diluted at a stock 
concentration of 30 mM in DMSO. PNU74654 (Sigma-Aldrich, Saint Louis, MO, USA.) 
was diluted at stock concentrations of 100 mM and 30 mM. H295R cells were plated at 
700,000 cells/well in 6-well plates. The cells were allowed to attach overnight and serum-
starved for 24 h. They were then treated with PKF115-584 (1, 2.5, 5 and 10 μM) or 
PNU74654 (3, 30 and 100 μM), at a final DMSO concentration of 0.1%, or with DMSO 
alone (vehicle). After 24 h of treatment, the cells were collected and RNA or protein was 
extracted from the cells.  
Protein extraction/immunoblotting. 
Cell pellets were re-suspended in RIPA protein lysis buffer and incubated on ice for 40 
min, then spun at 15,000 rpm for 15 min. For tissue protein extraction, RIPA buffer was 
supplemented with 10% glycerol for storage. 10-40 μg of total protein were heated to 95°C 
for 5 min in 1X sample buffer and run on 10% SDS-polyacrylamide gel at 150 V for 1 h. 
Protein was then transferred onto PVDF for 1 h at 100 V. The blots were blocked with 5% 
milk Tris-buffered saline-Tween 0.1% (TBS-T). To detect β-catenin, β-actin and RalA-
binding protein 1 (RALBP1), the blots were probed with mouse anti-β-catenin (1:2,000) 
(BD Transduction Laboratories, Franklin Lakes, NJ, USA), mouse anti-actin (1:2,000) 
(Sigma), or mouse anti-RALBP1  (1:500) (Abnova, Taipei City, Taiwan) overnight at 4°C.  
The blots were washed 3X with 1X TBS-T, and probed with anti-mouse horseradish 
peroxidase (Sigma) at 1:5,000-10,000 for 1 h. They were developed with ECL™ Western 
blotting detection reagent (GE Healthcare, London, UK) and exposed on X-ray film for 
varying time periods to achieve the best signal. 
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RESULTS 
Differential expression profile of AA with CTNNB1 mutations 
We compared the gene expression profile of 3 AA with CTNNB1 point mutations to 4 AA 
WT CTNNB1. 1,509 probe sets showed differential expression profiles between the 2 
groups with a t-test p-value of at least 0.05. Within the dataset, 128 probe sets 
corresponding to 114 genes/transcripts had a minimal mean expression ratio of 2 in 
tumours with CTNNB1 mutations. Forty-five probe sets (corresponding to 43 genes) with a 
minimal 3-fold difference in expression values are listed in Table 1.  Furthermore, 407 
probe sets, corresponding to 376 genes/transcripts, had a mean ratio of 0.5 or less. Eighty-
one probe sets (Table 2), corresponding to 75 genes, had a significant 4-fold decrease of 
expression in adrenal tumours with CTNNB1 mutations relative to WT adenomas.  
We deployed the PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
Classification System (http://www.pantherdb.org) (5) which classifies genes by their 
function. Among the 1,509 statistically significant probe sets, PANTHER recognized 22 
biological processes including over-expression of genes related to “developmental 
processes” (p=0.003) and “systems development” (p=0.003) (Supplemental Table 2). 
Moreover, the PANTHER system revealed over-representation of genes involved in Wnt 
signaling (Supplemental Table 3).    
We then analyzed the 1,509 probe sets, focusing on genes known to be related to Wnt/β-
catenin signaling available from the WNT homepage 
http://www.stanford.edu/~rnusse/wntwindow.html. Interestingly, 2 probe sets 
corresponding to ENC1 (ectodermal-neural cortex 1), known as a downstream target of β-
catenin/TCF complex which is upregulated in colon cancer, were over-expressed in 
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tumours carrying CTNNB1 missense mutations with a ratio of 6-fold (p<0.05) and 5.4-fold 
(p=0.1) (20). GJA1 (connexin 43) probeset, known to be regulated by β-catenin/TCF, was 
down-regulated in tissues with CTNNB1 mutations (0.243; p=0.008).  
 
RT-PCR validation of genes expressed differentially in adrenocortical tumours harbouring 
CTNNB1 mutations  
To validate the microarray data, 7 genes were selected for confirmation by RT-PCR.  ISM1 
(isthmin1, zebrafish homolog), RALBP1 (RalA-binding protein 1), PDE2A 
(phosphodiesterase 2A, cGMP-stimulated), CDH12 (cadherin-12), ENC1, PHYHIP 
(phytanoyl-CoA 2-hydroxylase interacting protein) and CITED2 (Cbp/p300-interacting 
transactivator with Glu/Asp-rich carboxy-terminal domain 2) were significantly de-
regulated in AA with CTNNB1 point mutations (n=3), compared to NA (n=10) and WT AA 
(n=13) (p<0.05) (Figure 1).  
The 2 highest over-expressed probes (28- and 32-fold, Table 1) on microarray analysis 
were C20orf82, now known as ISM1 gene.  RT-PCR studies confirmed the up-regulation of 
ISM1 in AA with point mutations, giving an average ratio of 65.6+12.2-fold  compared to 
either WT adenomas (p<0.001) and NA (p<0.001) (Figure 1). CDH12  over-expression was 
confirmed in AA with CTNNB1 point mutations for a ratio of 9.4 compared to NA 
(p<0.001) and 9.8+2.4 for WT AA (p<0.001) (Figure 1). Interestingly, although mean 
CDH12 expression in WT AA was not significantly different from NA, 6 out of 13 AA 
showed higher expression, and 6 of 13 under-expression, compared to NA. RALBP1 gene 
was over-expressed in AA with CTNNB1 point mutations by a mean factor of 4.7+0.3-fold 
and 4.8+0.4-fold, compared to NA and WT AA (p<0.001) (Figure 1). PDE2A was over-
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expressed compared to NA (10.1+1.6) and WT AA (10.6+2.2) (p<0.001) (Figure 1).  ENC1 
and PHYHIP genes were also over-expressed in 4 out of 5 and under-expressed in 5 of 5 
ACC, respectively.   RT-PCR validated the under-expression of PHYHIP and CITED2 (21) 
(Figure 1) in tumors with CTNNB1 mutations compared to NA tissues (-28+5.9-fold, 
p<0.001 and -4.2+0.9-fold, p<0.001, respectively) and WT AA (-21.8+5.9-fold, p<0.001 
and -3.9+0.8-fold, p<0.001).   
We then studied the expression of the 7 selected genes in 3 AA harbouring deletion 
mutations localized in exon 3 of CTNNB1 gene including 26,943 del 55 bp, 26,995 
delExon3(271 bp) and 27,127 del 6 bp (8). Similarly, as in AA with point mutations, 
significant increased expression of ISM1, RALBP1 and PDE2A was found in 2/3 AA with 
deletion mutations compared to NA and WT AA (Figure 1). ENC1 and CDH12 levels 
showed expression similar to NA and WT AA. Decreased PHYHIP and CITED2 
expression was respectively observed in 2/3 and 3/3 AA with deletions. Tissue with the 
26,943 del 55 bp presented an opposing trend of expression for the 7 genes except for 
CITED2 (Figure 1).  
The only ACC sample with CTNNB1 point mutations available over-expressed ISM1, 
PDE2A, RALBP1 and ENC1 compared to WT AA and ACC and NA with relative 
expression ratios of 63.0, 4.5, 2.24 and 18.0, respectively (Figure 1). However, this ACC 
showed decreased CHD12 expression compared to NA (23.0-fold). PHYHIP levels were 
reduced in ACC harbouring CTNNB1 point mutation compared to WT AA (137-fold) and 
WT ACC (36.7-fold). CITED2 was significantly down-regulated by 3.1- and 3.7-fold in 2/4 
WT ACC and disclosed 1.5-fold under-expression in ACC with CTNNB1 point mutation.   
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Antagonists of TCF4/β-catenin complex dose-dependently inhibit the expression of selected 
genes in human adrenocortical cell lines   
To support the hypothesis that the 7 selected genes were functionally related to CTNNB1 
mutations, we studied the effects of suppressing β-catenin transcriptional activity with 
antagonists of TCF4/β-catenin complex, PKF115-584 and PNU74654 SW13 (22) and 
H295R (23) cell lines. H295R cells carry the CTNNB1 mutation S45P (7, 8) which elicit 
nuclear accumulation of β-catenin and β-catenin/TCF interaction (Supplemental Figure 1). 
SW13 cells were considered as controls because they harbour no CTNNB1 mutation 
(personal data) and express low amounts of β-catenin (Supplemental Figure 1). RT-PCR 
demonstrated that ISM1, RALBP1, PDE2A, CDH12 and ENC1 genes were up-regulated in 
the H295R ACC cell line (40.6-, 4.8-, 5.3-, 41.7- and 3.6-fold, respectively) compared to 
NA (Supplemental Figure 2). Moreover, these genes were not over-expressed in non-
mutated SW13 cells. CITED2 was found to be down-regulated in H295R cells (5-fold) but 
not in SW13 cells. PHYHIP was very poorly expressed in both cell lines (data not shown) 
and was not further studied.    
RT-PCR was conducted to examine the effects on gene expression after treatment with  
PKF115-584, PNU74654 or vehicle for 24 h in H295R and SW13 cells. As expected, the 
pattern of gene expression was linked to β-catenin activity as seen in adrenocortical 
tumours with CTNNB1 mutations, except for PHYHIP and CDH12 (results not shown). The 
most potent effect was observed on ISM1 expression: 88+1.1% dose-dependent decrease of 
ISM1 expression after PKF115-584 and 74.1+4.3% after PNU74654 treatments in H295R 
cells (Figure 2). Similarly, PKF115-584 led to reduced expression of PDE2A (by 
35.9+5.0%) and RALBP1 (by 51.7+3.0%) at 10 µM. With PNU74654, PDE2A expression 
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levels were diminished by up to 50+14% whereas RALBP1 expression declined only 
slightly (by 25%) (Figure 2). mRNA ENC1 levels were significantly decreased by PKF115-
584  (45+13%) and PNU74654 (55.1+6.8%). In contrast, CITED2 levels increased after 
PKF115-584 treatments in H295R cells (194+28%) (Figure 3). As controls, we studied 
AXIN2 which is considered to be the most faithful gene for determining β-catenin/TCF 
activity (24, 25). As expected, AXIN2 levels were reduced by PKF115-584 (41.3+4.9%) 
and PNU7654 (47.3+8.2%) (Figure 3).  In SW13 cells, ISM1, PHYHIP, PDE2A and 
CDH12 expression was not determined because of their very low to undetectable levels 
(Supplemental figure 2). 
Validation of RALBP1 protein over-expression in adrenocortical tumours  
RALPB1 is a drug-transporter that can mediate drug-resistance (26) in lung  and kidney 
cancers (27). RT-PCR confirmed RALBP1 over-expression in 3/3 AA and 1/1 ACC with 
CTNNB1 point mutations, disclosing significant increases of 3.59+1.57-fold and 2.25+0.48-
fold, respectively, compared to NA (n=10, p=0.02) and WT CTNNB1 tumours (n=13; 
p=0.019) (Figure 1). Moreover, heightened expression of RALBP1 was noted in 2/3 
tumours with deletion mutations (Figure 1).   
Western blot analysis confirmed RALBP1 protein over-expression in 4/6 AA with 
CTNNB1 mutations (3.9+0.7-fold) and in 1/1 ACC with CTNNB1 point mutation (4.7+0.3-
fold). Interestingly, RALBP1 protein levels were elevated in 4/4 WT ACC (3.1+0.7-fold) 
(Figure 4) and detected at lower levels in WT AA (2+0.6-fold, n=5) compared to NA (n=6). 
mRNA RALBP1 expression decreased after treatment with PKF115-584 achieving an 
inhibition of 52%+2% (p<0.001) in H295R cells at 10 µM (Figure 2B). However, in WT 
71 
 
SW13 cells, there was no significant variation of RALBP1 or AXIN2 expression after 
treatment (results not shown). Furthermore, we found 61.4% reduction of RALBP1 protein 
expression after treatment with 5 µM of PKF115-584 in H295R cells (Figure 4D). As seen 
at the mRNA level, RALBP1 protein was only slightly diminished (by 19 +/- 4.6%) after 
24 h of treatment with 100 µM of PNU74654.   
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DISCUSSION 
In this study, we searched for new target genes of the Wnt pathway specifically de-
regulated in adrenocortical tumours with CTNNB1 mutations. We compared the expression 
profiles of these tumours to those without CTNNB1 mutations. Our approach was 
previously validated in Wilms tumours (28) and endometrioid adenocarcinomas (29)  and 
identified new target genes of Wnt/β-catenin specifically in these cancers. De-regulation of 
β-catenin results in the constitutive formation of β-catenin/TCF complexes and in the 
altered expression of TCF-regulated target genes, such as MYC (17) and CCND1 (18), as 
reported in colon cancer. However, it is strongly believed that the target genes of β-catenin 
are tissue-specific. Although CTNNB1 mutations are encountered in about 20% of 
adrenocortical tumours, no studies evaluating presumptive target genes of β-catenin in 
human adrenocortical tumourigenesis have yet been performed.   
We recognized 114 genes/transcripts that were significantly over-expressed in tumours with 
CTNNB1 mutations, compared to WT tumours. ISM1 had the highest over-expression and 
was up-regulated specifically in 6/7 adrenocortical tumours with CTNNB1 mutations, 
supporting β-catenin involvement in ISM1 transcription, as shown previously in zebrafish 
(30). CDH12 which is known to interact with the MCP1-Induced Protein; a mediator of 
angiogenesis was the second most up-regulated gene (31). We confirmed the up-regulation 
of ENC1 gene in 3/3 AA with point mutations and 4/5 ACC by RT-PCR. However, 
tumours with deletion mutations did not show ENC1 over-expression. Giordano et al. 
previously reported ENC1 over-expression in ACC by micorarray analysis as well (5, 32). 
RALBP1 which mediate drug-resistance in cancers was over-expressed in 5/6 AA and 1/1 
ACC with CTNNB1 mutations (26). RALBP1 down-regulation leads to a decrease of drug 
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resistance but also to apoptosis and regression of lung and prostate tumours in xenograft 
models (26, 33). RALBP1 has never been studied before in adrenocortical tumours.   
PDE2A is a dual-function phosphodiesterase capable of both cGMP and cAMP hydrolysis 
(34). Its over-expression was validated in 6/7 tumours with CTNNB1 mutations, compared 
to the 27 NA tissues and WT CTNNB1 adrenocortical tumours. Mainly expressed in 
glomerulosa cells in the adrenal gland (35, 36), PDE2A is stimulated by atrial natriuretic 
peptide (37, 38) which culminates in the inhibition of aldosterone production (36).  
We confirmed the under-expression of PHYHIP gene in all adrenocortical tumours with 
CTNNB1 mutations. Moreover, we observed PHYHIP down-regulation in all ACC. This 
finding was not surprising since, very recently, Giordano et al. reported PHYHIP down-
regulation in ACC compared to NA and AA, in a transcriptome-profiling study (32). 
The transcription co-factor CITED2 was specifically under-expressed in all AA harbouring 
CTNNB1 genetic alterations. Targeted disruption of CITED2 in mice results in adrenal 
agenesis (39). Moreover, CITED2 is activated by SF-1 in a dose-dependent manner in NCI-
H295R cells (40). Our study is the first to suggest a potential link between CITED2 and the 
Wnt/β-catenin pathway in adrenocortical tumourigenesis.   
Although candidate genes reported here may not be direct targets of β-catenin, ENC1 is 
known to be regulated by TCF/β-catenin and has recognized β-catenin/TCF-responsive 
upstream regulatory sequences (20). Moreover, CDH12, PDE2A and ISM1 were found to 
have 7, 5 and 4 potential putative binding sites for LEF-1/TCF, respectively, according to 
the general consensus sequence WWCAAWG/CTTWGWW (41).  
One of the limitations of our data is the small number of samples studied. We present 
complete data on 6 AA with CTNNB1 mutations, which are about 30% of all the AA 
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reported as mutated in the literature so far (n=21) (7-9, 42). Moreover, to identify target 
genes specifically related to β-catenin activation, we focused our microarray analysis on 
tissues harbouring point mutations because they showed higher β-catenin nuclear 
translocation than tissues with deletion mutations. In addition, among all CTNNB1 
mutations reported so far in adrenocortical tumours, point mutations were more frequent 
than other types of mutations with a  prevalence of 72% (23/32) (7-9, 42). Nevertheless, we 
examined whether our results in tumours with CTNNB1 point mutations were similar to 
those in tumours with CTNNB1 deletion mutations. ISM1, RALBP1, PDE2A and PHYHIP 
over-expression was confirmed in 2/3 tissues with deletion mutations. The third sample, 
which harboured CTNNB1 26,943 del 55 bp, showed an opposing trend of expression for 
the 7 genes, except for CITED2, which was under-expressed in 3/3 deleted mutant 
adenomas. We found no over-expression of ENC1 gene in AA with deletion mutations. 
This absence of up-regulation in tissues with deletion mutations may be explained by the 
fact that various types of mutations do not elicit equivalent stabilization of β-catenin and 
transcriptional activation of Wnt target genes (43). Interestingly, ENC1 and PHYHIP were 
also aberrantly expressed in 3/4 and 4/4 WT ACC, respectively, supporting common 
expression characteristics of tumours with CTNNB1 missense mutations and ACC.  
We then tested PKF115-584 and PNU74654 compound. PKF115-584 has previously been 
shown to alter β-catenin/TCF transcriptional activity in H295R cells (15) and other cancer 
models (44, 45), by interfering with β-catenin/TCF interaction which, consequently, affects 
proliferation and apoptosis. We demonstrated that both antagonists down-regulated the 
over-expressed ISM1, RALBP1, PDE2A and ENC1 gene. In addition, PKF115-584 up-
regulated the under-expressed CITED2 gene.   
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This study is a first attempt to identify genes specifically de-regulated in CTNNB1-mutated 
adrenocortical tumours. Our data led to the identification of new candidate genes that may 
be involved in adrenocortical tumourigenesis. Further investigations are needed to 
determine the functional significance of these genes in the development of AA and ACC. 
Nevertheless, our data may contribute to a better understanding of the role of Wnt-β-
catenin in adrenocortical tumourigenesis. 
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FIGURE LEGENDS 
Figure 1. Validation of Microarray results by RT-PCR. mRNA expression of (A) ISM1, 
(B) ENC1, (C) RALPB1, (D) PDE2A, (E) CDH12, (F) PHYHIP and (G) CITED2 in 
adrenocortical tissues. The results represent the mean of 2 experiments performed with 2 
different RNA extractions from each tissue. Real-time reactions were performed in 
triplicate. The results were subjected to 1-way ANOVA, followed by the Bonferroni test to 
determine statistical significance (p≤0.05) between groups and WT adenomas. NA: NA, 
AA: adrenocortical adenoma, WT: wild-type CTNNB1, PM: tissue with CTNNB1 point 
mutation, DM: tissue with CTNNB1 deletion mutation, ACC: adrenocortical carcinoma. 
Arrows denote data of the tissue with CTNNB1 26 943 del 55 bp. 
Figure 2. Effects of β-catenin/TCF inhibitors on gene expression of (A) ISM1, (B) 
RALBP1, (C) PDE2A and (D) ENC1 in H295R cells by RT-PCR. The cells were treated 
with PKF115-584 (left panels) (1, 2.5, 5 and 10 μM), PNU74654 (right panels) (3.3, 30 and 
100 μM) or vehicle (0.1% DMSO) for 24 h. Bars represent the means of 2 independent 
experiments, each in triplicate with real-time reactions performed in duplicate. Errors are 
shown as % standard deviation. *p≤0.05, **p≤0.01, ***p≤0.001. 
Figure 3. Effect of β-catenin/TCF inhibitors on gene expression of (A) CITED2 and (B) 
AXIN2 in H295R cells. The cells were treated with PKF115-584 (left panels) or PNU74654 
(right panels) or with vehicle (0.1% DMSO) for 24 h. Bars represent the means of 2 
independent experiments, each in triplicate with real-time PCR reactions performed in 
duplicate. Errors shown as %standard deviation. ***p≤0.001. 
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Figure 4. (A) Western blot disclosing RALBP1 over-expression at the protein level in 
adrenocortical adenomas (AA) with CTNNB1 point mutations (PM) and deletion mutations 
(DM) compared to wild-type adrenocortical adenomas (WT AA) and normal adrenal glands 
(NA). (B) Western blot analysis of RALBP1 in adrenocortical carcinomas (ACC) compared 
to NA. (C) Quantitative RALBP1 levels relative to β-actin in normal adrenal glands (NA), 
wild-type AA (WT AA) and ACC, and AA and ACC with CTNNB1 mutation (Mutant AA 
and Mutant ACC). (D) Western blot analysis of RALBP1, CTNNB1 (β-catenin) and β-actin 
after 24-h treatment with PKF115-584 and PNU74654 in H295R cells (left panel). Graph 
presenting the means of quantitative RALBP1 and β-catenin levels relative to β-actin in 
H295R cells from 2 independent experiments, each in triplicate (right panel). Errors are 
shown as % standard deviation. 
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Table 1. Summary of 45 probe sets corresponding to 43 genes with an intensity ratio of at least 3-fold in AA 
with CTNNB1 mutations (“Mutant”) compared to AA with WT CTNNB1 gene (“WT”) (p<0.05). Genes selected 
for validation are highlighted in bold.  
Affymetrix 
ID 
Gene title 
 
Gene 
symbol 
Mutant/WT 
ratios  p-value 
235182_at chromosome 20 open reading frame 82/ ISM1 C20orf82 30.07 0.005 
232888_at chromosome 20 open reading frame 82/ISM1  C20orf82 28.33 0.014 
207149_at cadherin 12, type 2 (N-cadherin 2) CDH12 25.79 0.039 
1563933_a_at phospholipase D family, member 5 PLD5 8.52 0.035 
221577_x_at growth differentiation factor 15 GDF15 8.40 0.044 
201341_at ectodermal-neural cortex (with BTB-like domain) ENC1 6.04 0.035 
223557_s_at transmembrane protein with EGF-like and 2 follistatin-like 
domains 2 
TMEFF2 5.78 0.035 
232286_at AF4/FMR2 family, member 3 AFF3 5.57 0,004 
204134_at phosphodiesterase 2A, cGMP-stimulated PDE2A 5.44 0.048 
201579_at FAT tumour suppressor homolog 1 (Drosophila) FAT 4.95 0.041 
203699_s_at deiodinase, iodothyronine, type II DIO2 4.83 0.026 
241954_at farnesyl-diphosphate farnesyltransferase 1 FDFT1 4.59 0.025 
220707_s_at FAD-dependent oxidoreductase domain containing 2 FOXRED2 4.50 0.027 
1566880_at AF4/FMR2 family, member 3 AFF3 4.37 0.003 
204428_s_at lecithin-cholesterol acyltransferase LCAT 4.33 0.019 
206361_at G protein-coupled receptor 44 GPR44 4.28 0.009 
244696_at AF4/FMR2 family, member 3 AFF3 4.04 0.000 
234040_at helicase, lymphoid-specific HELLS 4.00 0.025 
242549_at protein kinase D3 PRKD3 3.92 0.011 
1555382_at premature ovarian failure, 1B POF1B 3.91 0.010 
239455_at transcribed locus --- 3.87 0.016 
1553229_at zinc finger protein 572 ZNF572 3.84 0.039 
238139_at homo sapiens, clone IMAGE:4523945, mRNA --- 3.58 0.005 
212750_at protein phosphatase 1, regulatory (inhibitor) subunit 16B PPP1R16B 3.57 0.021 
201911_s_at FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 FARP1 3.43 0.041 
220640_at casein kinase 1, gamma 1 CSNK1G1 3.42 0.001 
233055_at protein kinase D3 PRKD3 3.40 0.045 
233884_at human immunodeficiency virus type I enhancer-binding protein 3 HIVEP3 3.26 0.001 
216228_s_at WD repeat and HMG-box DNA-binding protein 1 WDHD1 3.26 0.015 
1554910_at protein kinase D3 PRKD3 3.25 0.021 
239358_at farnesyl-diphosphate farnesyltransferase 1 FDFT1 3.22 0.043 
201596_x_at* keratin 18 KRT18 3.21 0.010 
1552390_a_at chromosome 8 open reading frame 47 C8orf47 3.14 0.024 
203069_at synaptic vesicle glycoprotein 2A SV2A 3.09 0.031 
235488_at RAS-like, family 10, member B RASL10B 3.03 0.031 
222361_at similar to tubulin, β8 LOC64322 3.02 0.002 
202844_s_at ralA-binding protein 1 RALBP1 3.00 0.000 
232027_at spectrin repeat containing, nuclear envelope 1 SYNE1 3.00 0.017 
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Table 2. Summary of 81 probe sets corresponding to 75 genes with an intensity ratio of 4-fold and less in AA 
with CTNNB1 point mutations compared to WT AA (p<0.05). Genes selected for validation are highlighted in 
bold. *Probes that were of poor quality or were unspecific for 1 sequence. IDEM la modification de table 1 si 
vous êtes d’accord Mutant: AA with CTNNB1 point mutations. WT: AA with WT CTNNB1 gene 
  
Affymetrix ID Gene title Gene symbol Mutant/WT ratio   p-value
240312_at similar to CG4768-PA LOC389895 0.007 0.013 
203924_at glutathione S-transferase A1 GSTA1 0.008 0.031 
232636_at SLIT and NTRK-like family, member 4 SLITRK4 0.019 0.031 
1557146_a_at hypothetical protein FLJ32252 FLJ32252 0.025 0.035 
213247_at sushi, von Willebrand factor type A, 
EGF and pentraxin domain containing 1 SVEP1 0.039 0.025 
219932_at solute carrier family 27 (fatty acid transporter), member 6 SLC27A6 0.05 0.041 
211748_x_at prostaglandin D2 synthase 21-kDa (brain) PTGDS 0.065 0.038 
204777_at spectrin repeat-containing nuclear envelope 2 SYNE2 0.07 0.050 
212444_at CDNA clone IMAGE:6025865 --- 0.072 0.030 
217767_at complement component 3 /// similar to complement C3 precursor C3 /// 
LOC653879 0.074 0.022 
200872_at S100 calcium-binding protein A10 S100A10 0.088 0.034 
202995_s_at fibulin 1 FBLN1 0.089 0.024 
201787_at fibulin 1 FBLN1 0.091 0.028 
209981_at cold shock domain containing C2, RNA-binding CSDC2 0.093 0.005 
228214_at transcribed locus --- 0.094 0.012 
202994_s_at fibulin 1 FBLN1 0.095 0.030 
206252_s_at arginine vasopressin receptor 1A AVPR1A 0.097 0.042 
1569785_at CDNA clone IMAGE:5287047 --- 0.1 0.003 
227826_s_at sorbin and SH3 domain containing 2 SORBS2 0.106 0.039 
202437_s_at cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 0.106 0.045 
202920_at ankyrin 2, neuronal ANK2 0.121 0.024 
220794_at gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 0.131 0.011 
207213_s_at ubiquitin-specific peptidase 2 USP2 0.134 0.011 
206410_at nuclear receptor subfamily 0, group B, member 2 NR0B2 0.135 0.005 
205999_x_at cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4 0.144 0.000 
206638_at 5-hydroxytryptamine (serotonin) receptor 2B HTR2B 0.145 0.020 
206742_at c-fos induced growth factor (vascular endothelial growth factor D) FIGF 0.146 0.031 
208607_s_at serum amyloid A1 /// serum amyloid A2 SAA1 /// SAA2 0.147 0.013 
229461_x_at neuronal growth regulator 1 NEGR1 0.147 0.014 
242524_at cerebellin 4 precursor CBLN4 0.15 0.013 
217292_at myotubularin-related protein 7 MTMR7 0.153 0.049 
227498_at CDNA FLJ11723 fis, clone HEMBA1005314 --- 0.157 0.032 
232081_at ATP-binding cassette, sub-family G (WHITE), member 1 ABCG1 0.158 0.004 
223582_at G protein-coupled receptor 98 GPR98 0.159 0.001 
202435_s_at cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 0.162 0.047 
209159_s_at NDRG family member 4 NDRG4 0.165 0.008 
204174_at arachidonate 5-lipoxygenase-activating protein ALOX5AP 0.171 0.042 
227271_at fibroblast growth factor 11 FGF11 0.178 0.029 
226213_at v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) ERBB3 0.182 0.039 
205325_at phytanoyl-CoA 2-hydroxylase interacting protein PHYHIP 0.187 0.002 
206698_at x-linked Kx blood group (McLeod syndrome) XK 0.196 0.022 
203837_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 0.196 0.043 
238673_at transcribed locus --- 0.199 0.004 
227598_at chromosome 7 open reading frame 29 C7orf29 0.203 0.000 
208189_s_at myosin VIIA MYO7A 0.203 0.036 
222247_at putative X-linked retinopathy protein DXS542 0.205 0.013 
215602_at FYVE, RhoGEF and PH domain containing 2 FGD2 0.207 0.016 
227506_at solute carrier family 16, member 9 (monocarboxylic acid transporter 9) SLC16A9 0.208 0.000 
219610_at Rho-guanine nucleotide exchange factor RGNEF 0.208 0.009 
201189_s_at inositol 1,4,5-triphosphate receptor, type 3 ITPR3 0.211 0.012 
203836_s_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 0.213 0.019 
224339_s_at angiopoietin-like 1 /// angiopoietin-like 1 ANGPTL1 0.215 0.037 
204955_at sushi-repeat-containing protein, X-linked SRPX 0.215 0.032 
209496_at retinoic acid receptor responder (tazarotene induced) 2 RARRES2 0.219 0.003 
203662_s_at tropomodulin 1 TMOD1 0.22 0.013 
231773_at angiopoietin-like 1 ANGPTL1 0.221 0.021 
236550_s_at zinc finger protein 311 ZNF311 0.221 0.012 
202308_at sterol regulatory element-binding transcription factor 1 SREBF1 0.221 0.004 
205727_at telomerase-associated protein 1 TEP1 0.222 0.016 
211864_s_at fer-1-like 3, myoferlin (C. elegans) FER1L3 0.224 0.039 
229378_at storkhead box 1 STOX1 0.224 0.028 
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230144_at --- --- 0.227 0.035 
213849_s_at protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), β 
isoform PPP2R2B 0.227 0.038 
229975_at transcribed locus --- 0.229 0.037 
228195_at hypothetical protein MGC13057 MGC13057 0.229 0.027 
212884_x_at translocase of outer mitochondrial membrane 40 homolog (yeast) TOMM40 0.229 0.016 
206645_s_at nuclear receptor subfamily 0, group B, member 1 NR0B1 0.23 0.039 
209613_s_at alcohol dehydrogenase IB (class I), β polypeptide ADH1B 0.23 0.018 
211726_s_at flavin containing monooxygenase 2 (non-functional) FMO2 0.234 0.030 
210073_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 ST8SIA1 0.236 0.010 
1558388_a_at family with sequence similarity 77, member D FAM77D 0.236 0.009 
1568190_at glutamic-oxaloacetic transaminase 1,  soluble (aspartate aminotransferase 
1) GOT1 0.238 0.031 
201010_s_at thioredoxin-interacting protein TXNIP 0.239 0.049 
201667_at gap junction protein, alpha 1, 43-kDa (connexin 43) GJA1 0.243 0.011 
207195_at contactin 6 CNTN6 0.245 0.012 
206171_at adenosine A3 receptor ADORA3 0.246 0.014 
203424_s_at insulin-like growth factor-binding protein 5 IGFBP5 0.246 0.017 
218487_at aminolevulinate, delta-, dehydratase ALAD 0.247 0.008 
239183_at angiopoietin-like 1 ANGPTL1 0.248 0.005 
217771_at golgi phosphoprotein 2 GOLPH2 0.249 0.025 
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Supplemental Figure 1. β-catenin status in adrenocortical cells. (A) Western blot of 
H295R and SW13 total protein extracts, cytoplasmic and nuclear fractions probed with 
anti-β-catenin antibody showing over-expression of β-catenin in H295R cells. Anti-β-actin 
antibody was used as control for total protein and cytoplasmic extracts and anti-histone H4 
for nuclear fraction. (B) Immunoprecipitation of TCF4 (IP TCF) in H295R and SW13 cells. 
TCF4/β-catenin-bound fraction has higher expression in H295R than in SW13 cells. Non-
immunoprecipitated fraction (flow through) was analyzed to detect TCF4-unbound β-
catenin and β-actin levels. 
A
B 
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Supplemental Figure 2. mRNA expression levels of ISM1, RALPB1, ENC1, PDE2A,  
CDH12 and CITED2 in H295R and SW13 cell lines relative to normal adrenal glands. The 
results represent the mean of 2 experiments performed with 2 different RNA extractions per 
tissue analyzed. Real-time PCR reactions were performed in triplicate.  
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Supplemental Table 1. Among the initial 1,509 probe sets statistically significant under 
Microarray analysis, PANTHER recognized 22 biological processes as being expressed 
differentially in adrenocortical tumors harbouring CTNNB1 mutations compared to WT AA 
(p<0.01). Multiple probe sets associated with the same gene were counted as 1. The 
expected count for each class is based on representation of total classified genes in the 
human genome. Individual genes may belong to multiple classes. Classes highlighted in 
bold are overrepresented in over-expressed and under-expressed genes. The “Unclassified” 
category refers to genes which have not been associated with any biological process. Probe 
sets corresponding to hypothetical protein or transcripts, chromosome open reading frames 
were excluded from analysis.  
Biological 
process 
Genes with under-expressed probe sets Genes with over-expressed probe sets
 # found # expected p-value # found # expected p-value
Unclassified 159 53.69 0.0000 94 31.88 0.000 
Developmental 
process 44 24.12 0.0000 25 14.32 0.003 
System 
development 33 16.32 0.0001 19 9.69 0.003 
Immune system 
process 38 21.12 0.0002 15 12.54 0.268 
Cell 
communication 54 35.08 0.0004 32 20.83 0.006 
Cell adhesion 23 10.71 0.0004 16 6.36 0.001 
Signal 
transduction 52 33.68 0.0005 30 20 0.011 
Ectoderm 
development 23 11.46 0.0011 14 6.8 0.008 
Nervous system 
development 21 10.11 0.0012 12 6 0.017 
Cell motion 17 7.75 0.0021 9 4.6 0.041 
Cellular process 68 50.29 0.0021 43 29.86 0.003 
Cell-cell 
adhesion 15 6.42 0.0021 10 3.81 0.005 
System process 30 17.81 0.0030 16 10.57 0.060 
Immune 
response 14 6.08 0.0033 3 3.61 0.511 
Response to 
stimulus 25 14.45 0.0049 8 8.58 0.509 
Sensory 
perception 13 5.69 0.0050 7 3.38 0.053 
Mesoderm 
development 22 12.28 0.0056 12 7.29 0.060 
Sex 
determination 2 0.12 0.0067 0 0.07 0.931 
Blood 
circulation 6 1.69 0.0074 1 1 0.735 
Lipid metabolic 
process 17 8.99 0.0090 9 5.34 0.086 
Muscle 
contraction 9 3.6 0.0107 2 2.14 0.639 
Cell-cell 
signaling 19 10.7 0.0109 9 6.35 0.184 
Heart 
development 0 2.93 0.0518 6 1.74 0.008 
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Supplemental Table 2. Genes related to Wnt/β-catenin signaling. 14 genes related to 
Wnt/β-catenin signaling were found to be de-regulated in adrenocortical adenomas with 
CTNNB1 point mutations compared to CTNNB1 WT by Microarray.  
Probe set Gene ID Implication Fold 
expression 
p-value 
204672_s_at ANKRD6 WNT signaling pathway 
Negative regulator 
1.93 0.008 
219889_at FRAT1 WNT signaling pathway 0.7 0.006 
213222_at PLCB1 WNT signaling pathway 
non-canonical 
2.03 0.05 
234040_at HELLS WNT signaling pathway 4 0.025 
207416_s_at NFATC3 WNT signaling pathway, 
Wnt3-independent 
0.73 0.043 
217656_at SMARCA4 Chromatin remodelling 0.711 0.022 
240297_at SFRP4 WNT signaling pathway 0.523 0.045 
207149_at CDH12 WNT signaling Cadherin 
pathway 
25.79 0.039 
203874_s_at SMARCA1 Chromatin remodelling 0.8 0.05 
213251_at SMARCA5 Chromatin remodelling 0.7 0.02 
231767_at HOXB4 WNT target gene 1.69 0.041 
201341_at ENC1 WNT target gene 6.04 0.035 
201667_at GJA1 (connexin 43) WNT target gene 0.243 0.08 
220640_at CSNK1G1 WNT signaling 3.42 0.001 
 
 
 
 
 
 
  
Chapter III. Discussion 
Our laboratory focuses on identifying Wnt/β-catenin pathway alterations and 
understanding the implications/effects of Wnt/β-catenin in adrenocortical tumourigenesis. 
Our laboratory was the first to find β-catenin mutations in adrenal adenomas (188). β-
catenin mutations are known to occur in about 20% of all adrenocortical tumours (benign 
and malignant). Theses mutations lead to tumour growth and progression. In the adrenal 
gland β-catenin is essential for development (143). At the beginning of this work, the 
effects of β-catenin mutations in the adrenal tumours had not been characterized and 
information was speculative. Relevance of the mutations in an adrenal tumour context was 
first demonstrated by Doghman et al (218), who demonstrated that the β-catenin/TCF 
inhibitor PKF115-584 inhibited growth and increased apoptosis of H295R cells (218). We 
have confirmed that this inhibitor as well as another inhibitor; PNU74654 which does affect 
H295R growth (results not shown). Recently, overexpression of  a stable β-catenin mutant 
in mice was shown to induce adrenal hyperplasia and promote malignancy (152). Given the 
importance of β-catenin, it is surprising that only a few studies (123-125, 127, 219, 220) 
have been performed to globally find β-catenin target genes in a specific context. We 
designed a microarray experiment to distinguish gene expression profile of 3 adenomas 
with wild-type β-catenin and 3 adenomas with β-catenin mutations. Wild-type β-catenin 
adrenal tissues may have sporadic cytoplasmic and sparse diffuse nuclear staining. In order 
to determine β-catenin regulated genes, samples used with mutations were selected based 
on availability and strong widespread nuclear and cytoplasmic staining throughout the 
tumour. 
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The microarray analysis lead to the identification of novel target genes that may be 
regulated by β-catenin specifically in adrenal tissues. Our preliminary analysis showed that 
most genes known to be regulated by β-catenin various cancers were not aberrantly 
expressed in tumours with β-catenin mutations suggesting that most genes deregulated by 
β-catenin in the adrenal gland are tissue specific. In fact only one gene, ENC1, wich was 
previously shown to be regulated by β-catenin/TCF (107) was highly overexpressed (over 
4-fold) in adenomas with CTNNB1 point mutations. ENC1 may contribute to colorectal 
carcinogenesis by suppressing cell differentiation (107) and has been linked to meningioma 
progression (221), but its role in adrenocortical tumourigenesis remains to be determined. 
ENC1 was also found to be generally overexpressed in ACC but less than in tumours with 
β-catenin point mutations. As mentioned earlier, up to 70% of ACC may have aberrant 
accumulation of β-catenin (Figure 13, page 48); hence it is not surprising that certain genes 
deregulated in ACC may also be deregulated in adenomas with β-catenin mutations.  The 
different levels of deregulation may be due to the fact that in some tissues aberrant 
accumulation of β-catenin may be heterogeneous across the tissue whereas the tissues 
harbouring β-catenin mutations that were studied in our microarray experiment had very 
high homogeneous nuclear accumulation of β-catenin as determined by IHC (previously 
(153) and results not shown). β-catenin nuclear accumulation is not the only element of 
gene expression that should be take into account since other co-factors may be required  
and this  may explain why β-catenin activity may lead to expression of genes other than 
those previously reported  in colon cancer. Microarray studies in other cancers (123, 126) 
have shown widespread difference in target genes and our results are in accordance to this 
variability between tissues. 
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ACCs and adenomas typically have very distinctive expression profiles(62), but 
ACCs often present β-catenin accumulation regardless of β-catenin mutational status (164).  
In regard to this fact, we searched for genes that were deregulated in our study compared to 
those found deregulated in ACC. Nine highly deregulated genes ENC1, PHYHIP, FIBLN1, 
GPR98, HTR2B, RARRES2, SEMA6A, LRRN3, SLC16A9 in tumours with β-catenin 
mutations were found previously deregulated in ACC by previous microarray studies (61, 
62, 187). In fact, the latter six genes have been found to be good diagnostic markers to 
differentiate benign and malignant adrenal tumours (222), and both ENC1 and PHYHIP are 
found overexpressed in ACC compared to adenomas and normal adrenal glands. Although 
the functionnal implications of these genes in adrenal cell proliferation/survival is yet 
unknown, these finding do supports the hypothesis that deregulation of the Wnt/β-catenin 
pathway may cause malignant growth potential.  
It is important to underline, that most genes identified as aberrantly expressed in 
tumours harbouring CTNNB1 mutations have not been well characterized and their role in 
the development of adrencortical tumours is unknown. In addition, most genes were not 
previously known to be linked to β-catenin. Although, previous studies reported a link 
betweenβ-catenin and Wnt signaling in adrenocortical steroidogenesis (via the transcription 
factor SF1) (151, 162), no genes involved in adrenal steroidogenesis (Figure 2, page 4) 
were aberrantly expressed in β-catenin mutant adenomas. β-catenin mutations are found in 
all types of secreting adrenal tumours as well as non-secreting adenomas and carcinomas. 
Therefore, this is highly suggestive that β-catenin mutations do not affect the hormonal 
secretion profile of adrenal tumours.   
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 In this study, we determined gene expression profile of 3 adrenocortical adenomas 
harbouring 3 point mutations in the CTNNB1 gene including the S45P, T41A and, S37C 
mutations. Previous studies showed that depending of the localisation of the mutations, 
activation of gene expression by β-catenin may vary (170, 223) and therefore mutations in 
the regulatory sites (S45, S33, S37, T41) have been shown to lead to different potential 
activation of gene expression. Hence variability between the three tissues in the expression 
of β-catenin target genes was expected and this may have lead to false negative results in 
regard to β-catenin target genes. This fact may explain why genes typically regulated by β-
catenin/TCF were not significantly differently expressed in our study.  In fact, the gene 
ENC1 was the only highly upregulated gene which was previously proven to be regulated 
by β-catenin/TCF (107). ENC1 was also shown to be upregulated generally in ACC.  As 
mentioned previously up to 70% of ACC (Figure 13, page 48) may have aberrant β-catenin 
accumulation, then it is not surprising that certain genes deregulated in ACC may also be 
deregulated in adenomas with β-catenin mutations. Aberrant accumulation of β-catenin 
may be heterogeneous but the mutant tissues selected for microarray analysis exhibit very 
high and homogeneous nuclear accumulation of β-catenin as detected by IHC (results not 
shown, and as described in Tadjine et al (153)) and this may explain why genes selected for 
validation were highly deregulated but in a lesser extent in  Wt ACCs. 
This study also permitted the identification of genes that had never been 
characterized in the adrenal gland. For example, although ISTHMIN 1/ISM1 expression has 
never been reported in human tissues, it was previously found as regulated by β-
catenin/TCF in zebrafish (224). ISM1 as well has CDH12 are apparently very weakly 
expressed in the normal adrenal but genes such as RALBP1 and PDE2A are quite readily 
expressed suggesting that WNT/β-catenin not only activates gene expression of a subset of 
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genes, but may increase expression of constitutively expressed genes in the adrenal gland 
directly or indirectly.  The low levels of ISM1 expression in normal adrenal glands and WT 
adenomas suggest little or no role of ISM1 in the adrenal gland. In Xenopus, ISM1 was 
found to be a secreted protein apparently involved in development (225). In mice ISM1 was 
recently found to have a  tumour suppressor role leading to inhibition of angiogenesis 
(226). If in fact β-catenin does directly lead to adrenal tumour formation, ISM1 may be 
activated as part of an auto regulatory loop, or hold a yet undetermined function in humans, 
as secreted proteins are known to potentially have contradictory roles in different contexts.  
RALBP1 was another gene of particular interest due to its well characterized role in 
drug resistance (227-230). In adrenocortical carcinomas, drug resistance to typical 
chemotherapeutic agents is quite high and it is why surgery is the only efficient treatment 
since the response to chemotherapy is poor (204). Multidrug resistance is brought in part by 
the multi drug resistance gene (MDR1) which encodes for a p-glycoprotein. MDR1 levels 
are high (231) in normal adrenal glands and adrenocortical tumours. Moreover, MDR1 
seems to be involved in aldosterone secretion (232). Drugs targeting p-glycoprotein activity 
have shown limited success in a clinical setting (233). Thus, RALBP1 may be a new 
potential drug target to counteract multidrug resistance in adrenal cancers.   
The CDH12 gene also chosen for further validation due to its high differential 
expression was found to have a high variable expression in all adenomas with highest levels 
in those with β-catenin mutations. Originally thought to be a brain specific protein, it has 
been now found to be linked to tumor progression in non-small-cell lung carcinomas (234). 
CDH12 is part of the cadherins family of proteins, cadherins are calcium-dependent cell-
cell adhesion molecules that mediate cell-cell binding to maintain cell:cell structures such 
as the epithelium. The impact of CDH12 on adrenal pathophysiology remains unknown.  In 
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Wt adrenocortical adenomas, its expression is either downregulated or over expressed 
suggesting that it is not involved in tumour survival/growth. Other cadherins such as E-
cadherin and N-cadherin are known to  interact with β-catenin mediating cell junction and 
differentiation. Whether or not β-catenin and CDH12 interact, warrants further study since 
our work with inhibitors of β-catenin transcriptional activity did not show clear effect on 
CDH12 expression (results not shown). 
We also validated expression levels of PDE2A in our adrenal samples. PDE2A is a 
phosdiesterase capable of hydrolyzing both cGMP and cAMP (235).  In adrenal glomerulosa 
cells, ANP (Atrial natriuretic peptide) activated PDE2A can block aldosterone 
accumulation by inhibiting cAMP (236). ANP is a peptide known to decrease secretarory 
responses in both the adrenal and pituitary gland (237). It is important to underline that in 
our microarray study we studied secreting-adrenocortical tumours whereas most β-catenin 
mutants found to date in other laboratories are in non-secreting lesions. Interestingly Wnt 
signaling has been linked to aldosterone secretion (151, 152, 162). In addition, forkskolin, a 
cAMP stimulator, leads to increased aldosterone levels in H295R cells despite the 
overexpression of PDE2A. In summary, PDE2A overexpression is probably not sufficient 
to affect hormone production without exterior activation, but increased PDE2A could 
provide an environment to decrease hormone production upon activation.  
 Most probes downregulated in adrenocortical tissues harbouring β-catenin 
mutations corresponded to partial transcripts and uncharacterized transcripts. 
Underexpressed CITED2 and PHYHIP genes were validated by real-time PCR. CITED2 
like β-catenin is essential to adrenal development. The significance of decreased expression 
of  CITED2 in adrenal tumor is not clear but in colon cancer increasing CITED2 leads to  
cell growth and inhibition of  cell invasion in RKO cells (238). PHYHIP has been 
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characterized as an angiogenesis and neuronal differentiation inhibitor (239). PHYHIP 
expression is known to be repressed by the transcriptional repressor AP4 (240). 
Interestingly AP4 interacts with β-catenin and leads to its nuclear translocation (241) which 
supports the possible involvement of β-catenin in regulation of PHYHIP levels in a TCF 
independent fashion.   
 The main drawback of our project is the limited number of samples studied. 
However we were limited by the clinical availability of adrenocortical tissues harbouring β-
catenin mutations. Due to the limited number of tissues studied, it is possible that 
subgroups of genes was found by chance in our dataset and are not linked to β-catenin.  
 Treatments of adrenocortical carcinoma cells H295R which harbour the CTNNB1 
S45P mutation with β-catenin/TCF inhibitors PKF115-584 and PNU74654 led to a 
decrease of ISM1, PDE2A, ENC1,RALBP1 expression which further strengthen the link 
between β-catenin and the expression of these genes. CITED2 mRNA expression in cells 
was increased upon treatment with PKF115-584 but not with PNU74654.  It is therefore 
possible that β-catenin regulates CITED2 in an alternative fashion. CITED2 levels can be 
regulated by FOXO3A (242). FOXO competes with TCF for interaction with β-catenin, 
therefore inhibiting TCF transcriptional activity (132) . FOXO overexpression leads to 
reduced TCF/ β-catenin binding after oxidative stress, which simultaneously increases 
binding between β-catenin and FOXO (132). Furthermore, small interfering RNA-mediated 
knock down of FOXO reverts loss of β-catenin binding to TCF after cellular oxidative 
stress(132). PKF115-584 may lead to oxidative stress (243) in cells and therefore could 
lead to an increase of β-catenin and FOXO  binding causing CITED2 overexpression.  
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Chapter IV. Conclusions 
Through the use of microarray technology we have identified new genes potentially 
regulated by β-catenin. Our dataset incuded genes with various functions such as 
cAMP/cGMP regulation, angiogenesis, proliferation and tumour survival. RALBP1 was 
found at the protein level to not be only overexpressed in mutant tumours but also in direct 
correlation to tumour status (normal <adenoma<carcinoma). Further work is needed to 
better understand the role of Ralbp1 in drug resistance of treatment of adrenocortical 
cancer.  Our work led also to the identification of ISM1, a newly discovered gene for which 
its implication in the adrenal gland is undetermined. Further studies using chromatin 
immunoprecipitation for example should be performed to confirm that ISM1 is a TCF/β-
catenin target.  
It must also be noted that our results, represent long term effects of β-catenin 
activation in a clinical perspective and thus most genes discovered to be deregulated in 
adrenocortical adenomas, with β-catenin mutations, may not be direct targets of β-catenin. 
We also highly agree that our data is based on a limited amount of tissues causing false 
positive and negative results and that this data would require confirmation with studies in 
future samples. CDH12 for example was upregulated in adenomas with β-catenin mutations 
but not in the ACC mutant and consequently no changes in CDH12 expression was 
detected upon treatment with β-catenin inhibitors in the H295R ACC cell line. However 
ISM1, PDE2A, ENC1, RALBP1 were postviely confirmed by inhibitor treatement, 
demonstrated probable β-catenin gene targets. Further work using more direct approaches 
such as chromatin immupopreciptation assays (CHIP), electrophoresis mobility shift assay 
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(EMSA) or promoter assays  will be  required   to determine and confirm genes directly 
regulated by β-catenin.  
Finally, we believe that this project was a first step in understanding the molecular 
effects induced by β -catenin mutations in adrenal tumours and strengthened that β-catenin 
regulated genes are context and cell specific. Studying the whole transcriptome of β-catenin 
mutant tumours provided numerous avenues for further research and potential new 
therapeutic targets in the management of patients affected by adrenocortical tumours. 
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